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ABSTRACT 
 
Glucocorticoids (GCs) are steroid hormones having a dual action with respect to 
differentiation and function of the bone-forming cells, osteoblasts. GCs are required for 
osteogenic lineage commitment and further differentiation, but at high and prolonged 
pharmacological dosage schedules, these drugs are harmful to mature cells leading to 
GC-induced osteoporosis (GIO). Despite previous studies, the exact mechanisms behind 
these complex effects are still not fully known. Therefore, this study was designed to 
characterize potential novel GC target genes in order to obtain further knowledge about 
the molecular mechanisms involved in the effects of GCs on bone health. 
During this thesis work, a new target gene for both GC and Wnt signalling 
pathways was identified in osteoblastic cells. Glutamine synthetase (GS) was found to 
be upregulated by GCs while downregulated by the Wnt pathway. Also calcitriol, i.e. 
active vitamin D, inhibited GS activity. GS could regulate the concentration of 
glutamate in osteoblastic cells thus controlling a third important signalling pathway, the 
glutamate signalling. We were also able to link GS to osteoblastic differentiation, and it 
could thus be even considered as a novel differentiation marker. Importantly, our results 
provide promising data for clarifying the molecular mechanisms behind the beneficial 
effects of therapeutic ultrasound (US) on bone healing as Wnt signalling was activated 
in the osteoblastic cells following US exposure. Furthermore, a novel mechanism for 
GCs to downregulate Wnt signalling pathway in bone was observed; Calreticulin- 
mediated nuclear export of the complex of glucocorticoid receptor and β-catenin was 
involved in the GCs ability to inhibit Wnt signalling in the osteoblastic cells.  
GS seems to be in a central position in the interplay between GC, Wnt, and 
glutamate signalling pathways, and thus its regulation may be crucial for the signal 
cross-talk mechanisms and intercellular communication in the bone environment. 
Furthermore, the inhibitory effect of GCs on Wnt signalling could explain, at least 
partly, the potential negative influence of GCs on mature osteoblasts that may lead to 
GIO. In addition, activation of the Wnt signalling pathway by US provides new 
information for the poorly known cellular mechanisms on which its bone healing 
properties are based on. More profound knowledge about the molecular mechanisms 
involved in bone cell differentiation and function could benefit prevention or treatment 
of GIO, fracture healing processes, tissue engineering technology with stem cells as 
well as assisting in the development of bone-friendly GC pharmaceuticals. 
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1. INTRODUCTION 
 
Bone is an active tissue which is being constantly remodelled. This means that old 
bone is removed while new is laid down by the cells present in bone, i.e., osteoclasts 
and osteoblasts, respectively. The remodelling process allows bones to adapt to physical 
loading and enables self-repair in the case of damage. Therefore, the balanced activity 
of these two cell types is a prerequisite for healthy bones. The skeletal integrity is 
maintained by many local and systemic regulators. At the cellular level, many 
transcription factors have been identified to control the proliferation and differentiation 
of bone cells, but knowledge about the signalling pathways involved in controlling these 
processes is far from complete. However, cells are known to receive a plethora of 
temporally and spatially distinct signals from their environment, and need to decide how 
to operate accordingly. These intra- and extracellular signals originate from soluble 
signalling molecules, which mediate the message to the receiving cell through specific 
receptors. Activation of these receptors triggers then distinct intracellular signalling 
pathways leading to various biochemical events. The specificity of the signal is thus a 
vital requirement. Earlier, it was believed that a single signalling cascade would be 
elicited from one receptor protein, but it was soon shown that this was an 
oversimplification, and subsequently cross-talk between different pathways has been 
characterized. Today, it is appreciated that cells contain a functional network of 
interacting signalling components, whose activity, stability, and subcellular localization 
are critical events in the regulation of the strengths of these pathways, and in that way, 
they govern the proliferation and differentiation of the cells in question.  
Glucocorticoids (GCs) are steroid hormones required for commitment of the 
mesenchymal stromal cells (MSCs) to the osteogenic lineage and for their further 
maturation process. On the other hand, with high and prolonged therapeutic doses, they 
evoke harmful effects to differentiated osteoblasts causing decreased bone mineral 
density and bone loss, i.e., GC-induced osteoporosis (GIO). The tissue-specific changes 
induced by GCs at the molecular level in bone are still poorly understood, as is the 
cross-talk of GC signalling with other pathways in the skeletal environment. Therefore, 
the aim of this thesis work was to study the GC-induced changes on the osteogenic 
16 
 
 
features of bone forming cells. Understanding how various signals are regulated and 
converted to biochemical responses in the target cells is of great importance. Deeper 
knowledge of the molecular mechanisms involved may well benefit, among many 
things, treatment of fractures and tissue engineering technology with stem cells as well 
as being of assistance in the development of bone-friendly GC pharmaceuticals. 
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2. REVIEW OF LITERATURE 
 
2.1 Osteoblast 
 
2.1.1 Status in the bone environment 
 
The human skeleton consists of more than 200 bones of varying sizes, shapes, and 
compositions. The function of these bones is to provide skeletal support, to protect vital 
organs, to serve as a site for hemopoiesis, and to act as a reservoir for calcium and 
phosphate in order to preserve normal mineral homeostasis. Bones are composed of the 
bone matrix and bone cells. The main organic component of bone matrix is type I 
collagen, but also small amounts of other collagens and several non-collagenous 
proteins, like osteocalcin (OCN), osteopontin (OPN), bone sialoprotein (BSP), and 
fibronectin are present. The extracellular matrix contains also inorganic material, mainly 
calcium-phosphate crystals, i.e., hydroxyapatite. Four main bone cell types originating 
from two separate cell lineages can be identified. The bone-forming osteoblasts 
(Kassem et al., 2008) synthesize the proteins of the extracellular matrix necessary for 
mineralization, whereas the bone-resorbing osteoclasts (Väänänen and Laitala-
Leinonen, 2008) are large, multinucleated cells that break down bone tissue. Osteocytes 
(Noble, 2008; Heino and Hentunen, 2008) are fully differentiated osteoblasts trapped 
into the newly formed osteoid, and represent the most abundant cells in mature bone. 
The role of osteocytes is to provide mechanical support, to control bone mineral content 
as well as to adapt bone in response to mechanical and chemical signals. Bone lining 
cells, for one, are also derived from osteoblasts and reside along the surface of most 
bones (Miller et al., 1989). They are thought to regulate the movement of calcium and 
phosphate into and out of bone, to transport nutrients, and to protect the quiescent bone 
surface from the extracellular fluid space.  
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2.1.2 Osteogenic lineage and differentiation 
 
Stem cells, in general, are a self-replicating heterogeneous population, giving rise to 
multiple cell lineages. Osteoblasts are derived from the multipotent MSCs of the bone 
marrow, although these cells are not necessarily considered to be genuine stem cells 
(Javazon et al., 2004). However, these progenitor cells do possess a multilineage 
potential, since in addition to osteoblasts, they are also able to differentiate into 
adipocytes, chondrocytes, fibroblasts, and myocytes, depending on the signals received 
(Pittenger et al., 1999; Caplan and Bruder, 2001) (Fig. 1.). Osteoclasts are derived from 
a different, hematopoietic origin, though. Surprisingly, there are also reports that MSCs 
can evolve into liver (Petersen et al., 1999), heart (Orlic et al., 2001), or vascular 
endothelial cells (Jackson et al., 2001). This trans-differentiation is, however, still 
questionable as it might be merely an in vitro effect or originate from the heterogenicity 
of MSC cultures (Kassem et al., 2008), and needs to be confirmed. Nevertheless, inter-
conversion of cells within the lineage boundaries is more likely to occur as, for 
example, adipocytes can be converted to osteoblasts, and vice versa (Nuttall et al., 
1998; Justesen et al., 2004). This is especially interesting in light of potential future 
therapies as the trabecular bone volume decreases and bone marrow becomes more fatty 
with aging (Justesen et al., 2001; Duque, 2008).  
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Fig. 1. A representation of the various cell lineages derived from the differentiation of MSCs. 
(Reprinted from Caplan and Bruder, 2001, with kind permission of Elsevier.) 
  
 
In addition to bone marrow, small amounts of MSCs can be also found in other 
tissues, like peripheral blood, adipose tissue, umbilical cord blood, and placenta 
(Zvaifler et al., 2000; Zuk et al., 2002; Romanov et al., 2003; Igura et al., 2004).  The 
exact location of the MSCs in the marrow or how they are recruited to the bone surface 
is still not exactly known. In vitro, these cells can be isolated from the bone marrow 
samples by plastic adherence. There are some stage-specific antigenic markers, like 
SH2-4, hOP-26, and STRO-1 (Simmons and Torok-Storb, 1991; Haynesworth et al., 
1992; Joyner et al., 1997) as well as CD13, CD29, CD44, CD73, CD90, CD105, 
CD106, and CD166 (Liu et al., 2008a), that could be used to select mesenchymal cell 
populations more specifically, but none of these approaches have yet been 
revolutionary. Specific external signals can commit cells to certain lineages. Isolated 
MSCs can be directed to osteoblastic lineage with chemically defined culture conditions 
by using usually GCs, ascorbic acid, and β-glycerophosphate needed for lineage 
20 
 
 
commitment, formation of collagen fibers, and as a source for phosphate groups, 
respectively (Beresford et al., 1993). The spindle shaped osteoprogenitors become large, 
post-proliferative cuboidal cells with a large nucleus, and preosteoblast condensation is 
observed. Preosteoblasts differentiate further into mature osteoblasts, known to form 
bone-nodules and mineralize the surrounding extracellular matrix, and finally into 
osteocytes or bone-lining cells in a multi-stage differentiation process. Naturally, this is 
a developmental continuum with no distinct boundaries.  
Osteoblastic differentiation is a well-coordinated process defined by stages of 
cellular commitment, proliferation, extracellular matrix maturation, and matrix 
mineralization. The first three stages are referred to as osteopoiesis whereas the final 
differentiation is called osteogenesis. Each step displays a characteristic expression 
profile of specific genes; Matrix proteins control the differentiation process, and the 
composition of the matrix changes as the tissue organization and mineralization 
develop. The committed post-proliferative preosteoblast expresses alkaline phosphatase 
(ALP), an early differentiation marker of the osteoblasts. This enzyme provides an 
optimal environment in which calcium can become attached to the new osteoid (Van 
Straalen et al., 1991). In addition, a novel osteoblast-specific marker, osteocrin, has 
been observed to be expressed during matrix formation (Thomas et al., 2003). The 
mature osteoblast is characterized by the expression of late calcium binding marker 
proteins, OCN and OPN, which are upregulated, especially, at the beginning of the 
mineralization phase. Although these two proteins are recognized as osteoblast-specific 
markers upregulated in conjunction with differentiation, their exact role in bone matrix 
formation is not fully understood and they can also be considered even as negative 
regulators of mineralization at later stages (Wolf, 1996; Huang et al., 2004). 
Nevertheless, osteoblasts can be recognized as cells expressing these specific marker 
proteins and by their ability to calcify extracellular matrix. If not terminally 
differentiated into osteocytes or bone-lining cells, osteoblasts finally die by apoptosis 
(Hock et al., 2001).  
All these phases of commitment and differentiation are tightly regulated, and MSCs 
and osteoblasts respond to many signalling molecules, hormones, cytokines, and growth 
factors (Datta et al., 2008; Nishimura et al., 2008). For example, bone morphogenic 
21 
 
 
proteins (BMPs), growth hormone, and insulin-like growth factors (IGFs) are known to 
be key regulators of bone development (Okamoto et al., 2006; Giustina et al., 2008). In 
addition, fibroblast growth factor (FGF), Hedgehog, Notch, and Wnt signalling 
pathways are major cascades reported to be involved in controlling osteogenic 
differentiation (Deng et al., 2008; Heino and Hentunen, 2008). (Fig. 2.) For instance, 
Notch signalling has been shown to inhibit osteoblast differentiation (Hilton et al., 
2008; Zanotti et al., 2008), whereas also an opposite result has been observed (Tezuka 
et al., 2002). FGF-8 and FGF-2 have been reported to be potential factors in directing 
bone marrow cells to osteoblasts (Valta et al., 2006) and for bone formation (Montero et 
al., 2000).  
 
 
 
 
 
Fig. 2. Major signalling pathways regulating osteogenic differentiation during skeletal 
development. These include FGF, IHH, Notch, BMP, and Wnt signalling pathways. FGF = 
fibroblast growth factor; IHH = Hedgehog; TGF-β = transforming growth factor β; BMP = bone 
morphogenic protein. (Reprinted from Deng et al., 2008, with kind permission of Frontiers in 
Bioscience.) 
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At the molecular level, there are several transcription factors controlling osteoblast 
differentiation, although the activation processes are not well known. Core-binding 
factor 1 (Cbfa1/Runx2) was the first osteoblast-specific transcription factor identified 
(Ducy et al., 1997). It is required for the differentiation of MSCs into osteogenic 
lineage, and it regulates the expression of several other genes such as collagenase-3, 
type I collagen, osteoprotegerin (OPG), ALP, BSP, OPN, and OCN (Ducy et al., 1999). 
Thus, the disruption of Cbfa1 prevents skeletogenesis (Komori et al., 1997). Osterix 
(osteoblast commitment factor) is another main transcriptional regulator acting 
downstream of Cbfa1, and its knock-out exerts similar phenotypic features as those seen 
in Cbfa1 deficient animals (Nakashima et al., 2002). Also ATF4 (activating 
transcription factor 4), TAZ (transcriptional modulator), TWIST, Id, homeodomain 
proteins Msx2, and Dlx5 are believed to play an essential role (Marie, 2008). 
Furthermore, main regulators for the other lineages derived from MSCs have also been 
characterized: peroxisome proliferator-activated receptor γ (PPAR-γ), Sox9, and MyoD 
for adipocytes, chondrocytes, and myocytes, respectively (Yanagisawa et al., 2007). 
(Fig. 3.) 
 
 
Fig. 3. Transcription factors involved in the differentiation steps of osteoblasts and expression 
of stage-specific marker proteins. Runx2 = Cbfa1, core-binding factor 1; ALP = alkaline 
phosphatase; Osx = osterix; BSP = bone sialoprotein. (Reprinted from Marie, 2008, with kind 
permission of Elsevier.) 
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2.1.3 Function in the bone remodelling process 
 
Bone is a metabolically active tissue; it undergoes rather significant turnover 
compared to other organs in the body. This means that old bone is resorbed and new 
bone laid constantly by the osteoclasts and osteoblasts, respectively. This maintains the 
strength and mechanical integrity of the skeleton by replacing old or damaged bone with 
fresh tissue. In healthy individuals, remodelling occurs at an estimated 1-2 million 
skeletal sites (Rodan and Martin et al., 2000), and this involves about 5-10% of the 
adult skeleton at one time. Therefore, complete skeletal renewal requires about a 
decade. The bone turnover continues throughout life, but the remodelling rate is faster 
in childhood, when bone formation exceeds resorption, while with aging, there is a net 
loss of bone. Impaired bone homeostasis due to imbalance in the function of the bone 
cells can lead to clinical problems such as bone deformities, fractures, osteoporosis, and 
abnormalities in the calcium and phosphate metabolism (Cohen, 2006). Therefore, bone 
remodelling, i.e., function of bone cells, must be strictly controlled by both systemic and 
local mechanisms.  
Remodelling is a highly organized process. The initiation of bone turnover is still 
not well known, but the signals for it are believed to originate from within the bone 
microenvironment. For example, osteocytes are able to sense mechanical loading and 
biochemical stimuli, and this could represent one mechanism for regulating the 
remodelling cascade (Klein-Nulend et al., 2003). The remodelling process can be 
divided into four phases: resorption, reversal, formation, and quiescence (Fig. 4.). In the 
first stage, bone lining cells retract from the bone surface and preosteoclasts form active 
osteoclasts starting the resorption process. Subsequently, osteoblasts are recruited to the 
resorption area and they produce new osteoid to be later calcified. This kind of turnover 
cycle takes approximately 3-6 months, but the rate varies according to the type of bone 
under study being faster in trabecular bone than in cortical regions (Datta et al., 2008). 
Furthermore, since resorption is a faster process than formation, an increased resorption 
rate may easily overwhelm a gradually increased bone formation.     
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Fig. 4. Bone cells and the remodelling cycle. At the beginning of the cycle, bone lining cells are 
retracted from the surface and osteoclasts start to resorb bone. Osteoblasts form new osteoid to 
be mineralized. Osteocytes are osteoblasts embedded inside the mineralized matrix and possess 
mechano-sensing and transducing properties. (Reprinted from Spencer et al., 2007, with kind 
permission of Elsevier.) 
 
 
Factors affecting the remodelling process are diverse and there may well be many 
still-to-be discovered factors. For example, various hormones, like parathyroid hormone 
(PTH) and growth hormone increase bone remodelling in order to mobilize calcium 
from the skeleton, while estrogens, androgens, calcitriol, i.e., active vitamin D, and 
calcitonin act in the opposite direction (Kenny and Raisz, 2002). Bone mass is also 
controlled by the hypophyseal FSH (follicle-stimulating hormone; Sun et al., 2006), and 
it is even shown to be under neuronal control via an energy metabolism related protein 
called leptin as low serum leptin levels lead to increased bone mass (Karsenty, 2006). 
Interestingly, OCN has recently been shown to have also hormonal function which has 
been linked to regulation of energy homeostasis (Lee et al., 2007). Furthermore, 
osteoblasts themselves are able to control osteoclast differentiation by secreting M-CSF 
(macrophage colony stimulating factor) and receptor activator of nuclear factor κB  
(NF-κB) ligand (RANKL), which interacts with its receptor, RANK, on the osteoclast 
cell surface. Osteoblasts can produce also OPG, a soluble decoy receptor for RANKL. 
Therefore, osteoblasts are able to both stimulate and inhibit osteoclast differentiation 
and in this respect they have an even more central role in the overall control of the 
remodelling process (Matsuo and Irie, 2008; Boyze and Xing, 2008). Furthermore, also 
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mechanical loading is considered one of the fundamental factors regulating the 
maintenance of bone mass due to its anabolic influences on the skeleton (Hillam and 
Skerry, 1995; Skerry, 2008). Ultrasound (US) represents one form of mechanical energy 
that can be transmitted to tissues as high-frequency acoustical pressure waves. Exposure 
to low-intensity US has been proven to be beneficial in bone healing processes (Claes 
and Willie, 2007), although the cellular mechanisms are still unclear. Understanding, 
how all these different regulatory signals combine to coordinate osteoblastic 
differentiation and bone cell function towards balanced bone remodelling, is naturally 
an important issue with respect to bone health. All the information obtained from the 
behaviour of the cells, especially osteoblasts, may be useful in terms of therapeutic 
development. Several of the regulatory pathways involved have already been proposed 
as potential drug targets for bone-related diseases (Martin et al., 2008), but there are still 
many unanswered questions. 
 
 
2.2 Glucocorticoid signalling and bone 
 
2.2.1 Glucocorticoid as a hormone 
 
The cells of adrenal cortex secrete GCs that are steroid hormones, essential to life. 
These steroids influence glucose homeostasis, protein, lipid, and carbohydrate 
metabolism, the aging process, memory, function of skeletal muscle, electrolyte 
balance, lung maturation as well as are known to have profound anti-inflammatory and 
immunosuppressive effects. GC synthesis is under the control of hypothalamic-pituitary 
axis, and adrenocorticotropic hormone is the major regulator of GC production 
systemically. (Norman and Litwack, 1997) The most important natural GC is 
hydrocortisone, i.e., cortisol. Its production exhibits a circadian rhytm: in the mornings, 
the normal serum cortisol concentration varies between 170 - 540 nM, while it declines 
towards the night being then 65 - 330 nM (Eastern Finland Laboratory Centre Joint 
Authority Enterprise, 2008). GCs are also commonly used to treat various chronic 
disorders such as autoimmune, pulmonary, and gastrointestinal diseases and are used in 
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patients following organ transplantation or in those with different malignancies. In 
addition to the natural hormone, there are several synthetic compounds, usually referred 
to as GC drugs, like dexamethasone (Dex), prednisolone, and betametasone, which have 
more potent anti-inflammatory effects and longer half-lives than the natural hormone. 
(Fig. 5.) The increased activity of these compounds is due to their higher affinity for the 
specific GC receptors (GRs) and delayed plasma clearance, which increases tissue 
exposure. (van deer Laan and Meijer, 2008) The dosage depends highly on the 
condition being treated, on the patient´s own cortisol production, and on the compound 
being used for the treatment, the average dose being 0.5-10 mg/day (Pharmaca Fennica, 
2008). Interestingly, GC treatment induces a negative feedback for the endogenous 
hormone production and therefore, the treatment always needs to be tapered off 
gradually. GCs are cholesterol-derived lipophilic compounds, which can diffuse through 
biological membranes. In the blood, natural GCs are mainly bound to a carrier, 
corticosteroid binding globulin (CBG, transcortin) and to a lesser extent to albumin. 
However, CBG does not bind all synthetic steroids, e.g., Dex is bound to albumin 
instead (Loew et al., 1986). GCs have also high affinity for mineralocorticoid receptors, 
for example, in the kidney tubules, but the rapid inactivation of the hormone to 
cortisone by 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2) in these cells normally 
prevents binding and further receptor activation thus preserving the specificity 
(Edwards, 1990).  
 
   
cortisol        dexamethasone 
 
Fig. 5. Structures of the natural GC cortisol, and of one synthetic compound, dexamethasone, 
used in this thesis work. As seen from the structures, GCs are cholesterol derivatives, and thus 
lipophilic.  
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2.2.2 Mechanism of action 
 
The biological effects of GCs are mediated by specific intracellular receptor 
proteins, GRs. They are ligand-inducible transcription factors belonging to the nuclear 
receptor family, which also includes receptors for mineralocorticoids, progestines, 
estrogens, and androgens as well as for non-steroidal thyroid hormones, retinoids, 
calcitriol, and orphan receptors with unknown ligands. GRs are present in virtually all 
tissues, and the ligand-receptor interaction is responsible for most of the known effects 
of this steroid. Like other receptors in this superfamily, GR can be structurally divided 
into functional domains: N-terminal domain (NTD), central DNA-binding domain 
(DBD), hinge region, and C-terminal ligand-binding domain (LBD) (Carlstedt-Duke et 
al., 1987; Heitzer et al., 2007). (Fig. 6A.) 
 
1 420 486 527 777
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Fig. 6. (A) Schematic presentation of the functional domains of human GRα. The receptor 
contains 777 amino acids corresponding to a molecular mass of about 90 kDa. NTD =             
N-terminal domain; DBD = DNA-binding domain; H = hinge region; LBD = ligand binding 
domain. (Reprinted from Heitzer et al., 2007, with kind permission of Springer Science.)        
(B) The three dimensional structure of the LBD of GR with the bound ligand, Dex (gray). 
(Reprinted from Ray et al., 1999, with kind permission of the Endocrine Society.) 
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The NTD is rich in negatively charged acidic amino acids, and contains a powerful 
transcriptional activation function (AF-1), which can interact with the basal 
transcriptional machinery and other co-regulators. It is able to activate target genes also 
in a hormone-independent fashion. The centrally localized DBD is a 66-amino acid 
region containing two groups of four cysteines, each group coordinately binding one 
zinc atom (Fig. 16., p. 74). These zinc finger motifs allow the receptor-DNA interaction. 
The N-terminal zinc finger recognizes the appropriate DNA response elements, while 
the C-terminal one is required for the receptor dimerization. The DBD region also 
contains a nuclear export signal (NES). Also the LBD participates in the dimerization 
and transcriptional control, and it contains another activation function (AF-2), which is 
ligand-dependent and weaker than the AF-1. The LBD recognizes and binds the cognate 
hormone, and contains one of the two nuclear localization signals (NLS). Heat shock 
protein 90 (HSP90) also binds the LBD. The hinge region provides the receptor 
molecule with flexibility and ability to change its conformation, and it contains the 
major NLS of the molecule, although this overlaps marginally with DBD. (Kumar and 
Thompson, 2005; Heitzer et al., 2007) Also a novel nuclear retention signal has been 
identified at the hinge region (Carrigan et al., 2007).   
Expression of GR is ubiquitous and it occurs in two isoforms: alternative splicing of 
the human primary transcript generates hGRα (777 amino acids) and hGRβ (742 amino 
acids) which share the 727 N-terminal amino acids (Encio and Detera-Wadleigh, 1991). 
GRα is the predominant isoform, while the latter neither binds the hormone nor 
transactivates the target genes, but more likely operates as a ligand-independent 
regulator of GC action, since it can act as an inhibitor of GRα activity (Bamberger et al., 
1995). Furthermore, the β-form is usually expressed at lower levels. In addition, 
alternative translation initiation sites have been characterized for both isoforms. At least 
eight optional sites are known for hGRα (Lu and Cidlowski, 2005). All of them result in 
receptors differing in their N-terminal region with identical DBDs and LBDs. 
Therefore, it is possible that they have variable transcriptional activities or cellular 
distributions, but this remains to be clarified. GR activity can be further modulated by 
various post-translational modifications, such as phosphorylation and sumoylation. 
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These modifications can affect the subcellular localization and/or stability of the 
receptor. (Duma et al., 2006)  
As lipophilic and non-ionic compounds, GCs can readily diffuse through the cell 
membranes. In the target cell, GCs bind to the cytoplasmic receptor molecules which 
are then released from the heteromeric complexes containing HSPs (HSP90, HSP70, 
and HSP56), one immunophilin (TPR (tetratricopeptide repeat) protein; FKBPs, PP5, or 
Cyp40), and p23 (Pratt and Toft, 1997; Heitzer et al., 2007). HSPs serve as chaperones 
and prevent DNA binding without the ligand, while keeping the receptor in its optimal, 
high affinity conformation for hormone binding (Bertorelli et al., 1998). Consequently, 
NLSs are exposed, receptor conformation changed and the hormone-receptor complex 
is translocated into the nucleus. Once there, it binds as a homodimer to the GC response 
element (GRE) in the target genes, and modulates their expression. (Fig. 7.) These 
GREs contain usually two sets of six-base pair long sequences separated by three base 
pairs, with the consensus sequence for GR being GGTACAnnnTGTTCT (Beato et al., 
1987). The ligand-bound GR can interact with both positive or negative GREs, leading 
to either activation or repression of transcription. The ligand binding leads to a change 
in the position of helix 12 in the LBD (Fig. 6B.), and subsequently, co-regulators (co-
activators or co-repressors), basal transcriptional machinery, and RNA polymerase II 
are recruited to the target gene (Kumar and Thompson, 2005). Interaction of the 
liganded GR with a GRE requires only a few minutes, and transcriptional changes can 
be detected from 15 min to a few hours depending on the target gene (Kumar and 
Thompson, 2005). GR can also affect transcription by modulating the access of other 
transcription factors, such as NF-κB and AP-1 (activator protein 1), to their DNA 
sequences. The sensitivity of tissues to GCs depends on the binding affinity of the 
receptor to GREs, its interaction with co-regulators and transcription factors, and the 
expression level of the receptor as well as on the concentration of the ligand. 
Interestingly, GCs themselves downregulate the expression of their own receptor 
protein, for example, by increasing the rate of receptor degradation via the ubiquitin-
proteosome pathway (Wallace and Cidlowski, 2001). The GC signal transduction can 
also be silenced by metabolism of the ligand as well as by regulating the rate of nuclear 
import and export of the receptor molecules (Kumar et al., 2006).  
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Fig. 7. The classical nuclear receptor-mediated GC signalling pathway. Hexagon = GC ligand; 
GR = glucocorticoid receptor; HSP90 = heat shock protein 90; TPR = tetratricopeptide repeat 
protein; CoA = co-activator; CoR = co-repressor; Pol = RNA polymerase II. (Reprinted from 
Heitzer et al., 2007, with kind permission of Elsevier.) 
 
 
In addition to the classical mechanism of action, GCs may also exert their effects 
via non-genomic ways (Bartholome et al., 2004). These effects are more rapid than 
those achieved through gene regulation, but they have long been under debate. Three 
different mechanisms have been proposed: 1) non-specific interactions of GCs with 
cellular membranes thereby changing the actions of membrane-bound proteins,            
2) effects mediated via factors released from the complexed cytosolic GR, or 3) specific 
interactions with membrane bound receptors which are putative variants of the cytosolic 
form (Stahn et al., 2007). One hypothesis is that CBG can bind to cell surface receptors, 
and cortisol may then bind to the CBG-receptor complex and activate adenylate cyclase 
and further cellular signalling systems. Also GC-induced changes in membrane fluidity 
and ion channel activity have been proposed (Haller et al., 2008).  
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2.2.3 Effects on bone health and on osteoblasts  
 
Although the indications for GC treatment in diverse clinical conditions are clear, 
long-term use of these steroids is associated with numerous side-effects. This is also the 
case with chronic pathological disorders in which the endogenous GC production is 
increased, e.g., in Cushing´s syndrome. The skeleton is especially vulnerable to excess 
GCs, and GIO is the most common form of secondary bone-loss (van Staa, 2006; 
Canalis et al., 2007). Osteoporosis is characterized as a condition with lowered bone 
mineral density and increased risk of fracture. GCs are known to increase renal calcium 
elimination and to decrease intestinal absorption of calcium leading to negative calcium 
balance, and thus its further release from bones. In addition to these systemic effects, 
GCs also affect the function of bone cells (Fig. 8.). Suppression of bone formation is 
one central feature in the pathogenesis of GIO. Osteoblasts and osteocytes express GRs 
(Chen et al., 1977; Haussler et al., 1980; Abu et al., 2000) indicating that GCs can have 
direct effects on their function. Also rat osteoclasts seem to possess GRs (Silvestrini et 
al., 1999), but interestingly there are opposite results on human cells (Abu et al., 2000) 
indicating possible indirect effect of GCs on human osteoclasts. On the other hand, GCs 
have been reported to have direct effects on these cells as well (Hirayama et al., 2002).  
GCs have been shown to modify the proliferative and metabolic activity of 
osteoblasts as the inhibition of proliferation and matrix formation is associated with 
changes in expression of several proteins like OCN, OPG, OPN, fibronectin, 
collagenase, IGFs, BSP, and BMP-2 (Reid, 1998). Especially, GCs decrease type I 
collagen and IGF-I synthesis, Cbfa-1 expression, and modify the function of 
transforming growth factor β (TGF-β) (Canalis and Delany, 2002). GCs also inhibit the 
activity of important signalling pathways, like Wnt cascade (Ohnaka et al., 2005). They 
delay osteoblastogenesis and reduce the lifespan of the cells by inducing apoptosis of 
both osteoblasts and osteocytes, a property also confirmed in transgenic mice (O´Brien 
et al., 2004), and favour osteoclastogenesis and osteoclast function by suppressing the 
synthesis of OPG and stimulating RANKL synthesis by the osteoblasts (Kim et al., 
2007; Kondo et al., 2008). It has been estimated that GCs may alter the expression of 
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over 500 genes as identified by the gene expression analysis of human primary 
osteoblasts (Hurson et al., 2007).  
Various therapies are available for the treatment of osteoporosis: calcium and 
calcitriol supplementation, hormone therapy mainly with estrogens and calcitonin as 
well as bisphosphonate treatment (Mazziotti et al., 2006; Liu et al., 2007). For example, 
estrogens are known to inhibit GC-induced osteocyte apoptosis (Gu et al., 2005). Most 
of the present therapies are, however, targeted against bone resorption rather than 
stimulating bone formation although that might even be a more efficient approach. 
Despite the calcium releasing properties of continuously infused PTH, short term 
exposure to its recombinant peptide (amino acids 1-34) is a known pharmacological 
agent currently known to stimulate bone formation (Neer et al., 2001). Another 
approved pharmaceutical for increasing bone formation is strontium ranelate (Tournis et 
al., 2006).   
 
 
Fig. 8. Direct and indirect effects of GCs on bone cells and on bone health. RANKL = receptor 
activator of nuclear factor κB ligand; CSF = colony-stimulating factor; GH = growth hormone; 
IGF-I = insulin-like growth factor I. (Reprinted from Canalis et al., 2007, with kind permission 
of Elsevier.) 
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Although GCs are well-known for their inhibitory effects on the mature osteoblast 
function, they are also required for the osteogenic lineage commitment and 
differentiation of the osteoblastic cells (Bellows et al., 1987; Cheng et al., 1994). On 
contrary to previously mentioned studies, GCs are also reported to positively regulate 
the osteoblast-specific markers as they can stimulate collagen type I, Cbfa1, and ALP 
expression, while inhibit expression of collagenase and matrix metalloproteinase 1 in 
normal human osteoblasts and osteoblast-like cells (Lajeunesse et al., 1991; Igarashi et 
al., 2004; Eijken et al., 2006). Furthermore, in the study by Eijken and co-workers, 
apoptotic cells were not detected in human primary osteoblasts treated with GCs (Eijken 
et al., 2006). Mechanistically, a novel GILZ protein (GC-induced leucine zipper) has 
been identified to regulate osteogenic differentiation of MSCs by upregulating the 
expression of the classical differentiation markers and mineralization while inhibiting 
PPAR-γ and adipogenic conditions (Zhang et al., 2008b). Furthermore, the sensitivity of 
osteoblasts to GCs can be modified by the 11β-HSD enzymes at the pre-receptor level: 
11β-HSD1 converts inactive GCs to active metabolites, while 11β-HSD2 catalyzes the 
opposite reaction. Both these forms are expressed, at least, in rat and human osteoblasts 
(Cooper et al., 2000; Eyre et al., 2001) thereby affecting the cellular responses. In the 
absence of GCs, human osteoblasts were shown to induce 11β-HSD1 expression thus 
providing an intrinsic control for proper differentiation process (Eijken et al., 2005). 
Studies with transgenic mice with osteoblast-targeted disruption of GC signalling by 
activation of 11β-HSD2 provided good evidence for the role of endogenous GCs in 
bone: femoral bone area and thickness were lowered compared to the wild-type mice, 
and OCN expression and mineralization were markedly reduced in osteoblasts derived 
from these knock-out animals (Sher et al., 2006). These results are contrary to the ones 
shown by O´Brien and co-workers, who reported induced transgene expression later 
(O´Brien et al., 2004), but this discrepancy may be explained by the differential 
temporal onset and level of transgene expression.  
Thus, it is clear that the effects of GCs on bone cells are variable and complex, and 
many actions seem to depend on the dosage, onset, and duration of the steroid exposure 
as well as on the differentiation status of the cells, or species under study. For example, 
mouse osteoblasts seem to differentiate without GCs, which is apparently not possible 
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for human cells (Ecarot-Charrier et al., 1983). It seems that GCs are necessary in the 
early phases of osteopoiesis, but these same hormones have detrimental influences 
during the later stages. It is probable that once the cells have entered the osteogenic 
pathway, the mineralization process can proceed independently of GCs (Eijken et al., 
2006). Skeletal problems are clearly more likely to arise with pharmacological GC 
dosages, and it is estimated that the fracture risk increases with use of more than 5 mg 
GCs/day (van Staa et al., 2000). However, one has to bear in mind that GCs are also 
present constantly in the body, and naturally, bone health is affected by the normal 
serum GC concentration as well (Dennison et al., 1999). Supposedly, the physiological 
levels are beneficial for bone, but how this normal production of GCs affects bone cells, 
is far less studied. Furthermore, it has also been suggested that the effects of GCs could 
be only positive for osteoblasts, and the negative effects leading to GIO could result 
solely from their action on osteoclasts, and from the systemic effects concerning other 
tissues, like kidneys and parathyroid glands (Eijken et al., 2006). 
 
 
2.3 Wnt signalling and bone  
 
The Wnt signalling pathway is a conserved cascade which plays an important role 
in the development of many organs and tissues as well as in aetiology of diseases, like 
cancer and degenerative disorders (Johnson and Rajamannan, 2006). Most of the 
preliminary data of Wnt signalling has been collected from the studies with Drosophila 
fruit flies, but similar features have also been identified later in higher organisms as 
well. Wnts are powerful regulators of cell proliferation and differentiation. They are 
secreted, lipid-modified glycoproteins rich in cysteine residues and known to bind to the 
Frizzled receptors (Wang et al., 2006). These receptors have an extracellular Wnt 
binding domain, a seven-transmembrane-spanning sequence and an intracellular           
C-terminal tail. The regulation of ligand binding to Frizzled receptors is one restriction 
point in Wnt signalling. To date, at least three distinct intracellular signalling pathways 
for Wnts have been characterized. One is known as the planar cell polarity pathway, it 
signals through the c-Jun N-terminal kinase (JNK) route, and mainly operates during 
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early embryogenesis (Lawrence et al., 2007). The second pathway, Wnt/Ca2+, is 
involved in cell migration and relies on protein kinase C activation (Kühl et al., 2000). 
In some instances, even an additional route with protein kinase A activity has been 
described (Torii et al., 2008). The signalling events of these so-called non-canonical 
pathways are, however, not well known, and distinguishing between them is difficult, 
since they share similar second messenger systems, mainly involving Ca2+, JNK, and  
G-proteins. The third and best characterized pathway is the canonical Wnt/β-catenin 
signalling pathway. The majority of data concerning Wnt signalling and bone health 
involve this pathway, although recent studies have also revealed a potential role of non-
canonical pathways (Tu et al., 2007; Günther and Schüle, 2007).  
 
 
2.3.1 The canonical pathway 
 
From the multiple different Wnt ligands identified, canonical Wnts include at least 
Wnt1, Wnt3a, Wnt8, and Wnt10b, but sometimes the same Wnt ligands can activate 
both β-catenin-dependent and -independent cascades determined by the cellular or 
functional context. However, the term canonical pathway is generally used only when 
β-catenin, the central regulator, is involved. In the absence of the Wnt signal, the 
cytoplasmic β-catenin concentration is maintained at very low levels. Axin, 
adenomatous polyposis coli (APC), casein kinase I (CKI), glycogen synthase kinase 3β 
(GSK3β), and β-catenin bind together to form a ternary complex in the cytoplasm. 
According to its name, GSK3β was originally identified as an enzyme of glycogen 
metabolism but later its role also in Wnt signalling was noted. β-catenin has a consensus 
phosphorylation sequence for CKI and GSK3β, and Axin greatly enhances this latter 
phosphorylation, which is required for the binding of the β-TrCP (β-transducin repeat 
containing protein) and ubiquitination of β-catenin. Hence, β-catenin is targeted to the 
proteosome complex and degraded. (Orford et al., 1997; Dale, 1998; Hinoi et al., 2000) 
In response to extracellular Wnt signal, however, a heterotrimeric complex of 1 of 
19 potential Wnt ligands, 1 of 10 possible Frizzled receptors, and 1 of 2 co-receptors 
(low density lipoprotein receptor-related proteins 5 & 6; LRP5/6) is assembled on the 
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cell surface. The mechanism underlying the selectivity of specific Wnts and receptors 
for the complex is not yet understood. Nevertheless, complex formation leads to 
phosphorylation of LRP5/6 which allows binding of Axin to the cytoplasmic tail of 
LRP5/6. Further activation of Dishevelled and APC induces inhibition of GSK3β 
through its phosphorylation of Ser9. This results in the collapse of the degradation 
complex and intracellular accumulation of β-catenin and its further translocation to the 
nucleus, where β-catenin interacts with the T-cell factor (TCF) / Lymphoid enhancer 
binding factor (Lef) family of transcription factors. This binding displaces corepressors 
like Groucho/Tle and histone deacetylases from the complex leading to activation of 
target gene expression. Transcriptionally active β-catenin alone lacks the DNA binding 
domain present in TCF/Lef molecules but on the other hand, they are poor 
transcriptional activators themselves, so only the complex is functional. (Dale, 1998; 
Shitashige et al., 2008) (Fig. 9.) In addition to the mechanism mentioned above, there 
may well be other ways to stabilize β-catenin (Kikuchi et. al., 2006). 
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Fig. 9.  Action of the canonical Wnt signalling pathway shown with and without active Wnt 
signal. LRP = low density lipoprotein receptor-related protein; CKI = casein kinase I; GSK3β = 
glycogen synthase kinase 3β; APC = adenomatous polyposis coli; TCF = T-cell factor; Lef = 
lymphoid enhancer binding factor; β-TrCP = β-transducin repeat containing protein. (Reprinted 
from Miller, 2001, with kind permission of BioMed Central.) 
 
 
2.3.2 Regulation of the canonical signal transduction 
 
Wnt signalling pathway is tightly regulated at multiple stages along the cascade. 
There are a number of extracellular proteins that can regulate the action of Wnt ligands 
and thereby activity of the Wnt pathway. These regulatory proteins interact with either 
LRP5/6, Frizzled, or the Wnt proteins on the cell surface. Secreted Frizzle-related 
proteins (sFRPs), Wnt inhibitory factor 1 (WIF-1), and Cerberus can directly bind to 
Wnt proteins and interfere with their binding to Frizzled. sFRPs can also bind to the 
receptor itself. Dickkopfs (Dkk), Sclerostin, and SOST, for one, interact with the LRPs 
and prevent formation of the Wnt-Frizzled-LRP complex. (Kawano and Kypta, 2003; 
Semënov et al., 2005; Glass and Karsenty, 2006) Dkk-1, for example, binds to LRP and 
38 
 
 
to a transmembrane molecule Kremen, which leads to internalization of LRP thus 
making it unavailable for Wnt reception (Mao et al., 2002).  
The key intracellular regulator within the pathway is the 92-kDa β-catenin molecule 
(Willert and Nusse, 1998). It can be found in three subcellular forms: membrane-bound, 
cytosolic, and nuclear forms. It was first found in association with the intracellular 
domain of E-cadherin and α-catenin, as a component of the adherens junctions in cell-
cell contacts. This interaction is known to be regulated, at least, by tyrosine 
phosphorylation of β-catenin (Piedra et al., 2001). Later, its dual role also in direct 
transcriptional control of target genes was elucidated. β-catenin has a 130 amino acid  
N-terminal domain, 12 imperfect repeats of 42 amino acids (the armadillo repeats), and 
a C-terminal domain of 100 amino acids. The armadillo repeats serve as binding sites 
for many interacting proteins and are necessary for nuclear translocation (Funayama et 
al., 1995). C-terminus functions as a transcriptional activation domain, while the         
N-terminal domain is important for the stability of β-catenin by containing several 
serine and threonine residues, which can be phosphorylated. These are the 
phosphorylations that signal for the proteosomal degradation of β-catenin. Based on 
recent studies, β-catenin can also be degraded independently of GSK3β phosphorylation 
via another complex containing Siah-1 (Liu et al., 2001). Nevertheless, stabilization and 
nuclear translocation of β-catenin appear to be central regulatory events in the 
transduction of the Wnt signal, although also contrary data has been proposed 
(Tolwinski and Wieschaus, 2004).  
In the nucleus, the availability of TCF and Lef is essential for the target gene 
regulation. TCF can also bind to its target DNA without the complex, and is therefore 
suggested to be a transcriptional repressor in the absence of β-catenin. In addition, 
phosphorylation of TCF inhibits the binding of the complex to DNA. (Kikuchi, 2000)  
A nuclear protein Chibby has been found to inhibit the transcriptional activity of          
β-catenin by interacting with its C-terminal region and competing with Lef-1 from 
binding to β-catenin (Takemaru et al., 2003). This antagonist has been recently 
connected with adipocyte differentiation (Li et al., 2007). Duplin and ICAT are other 
molecules that are able to inhibit Wnt signalling by competing with TCF-4 for the 
binding to β-catenin (Kobayashi et al., 2002; Tago et al., 2000). Generally, Wnt 
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signalling is associated with transcriptional activation of target genes, but it is also 
known to repress gene expression. This control probably depends on other general or 
Wnt specific co-regulators temporarily available in the nucleus of the cells in question. 
An updated list of Wnt target genes is available in the Wnt Homepage provided by      
Dr R. Nusse (Wnt Homepage, 2008). 
  
 
2.3.3 Relevance for osteoblast function and bone health  
 
During recent years, Wnt signalling pathway has been recognized as one of the 
essential regulators of osteoblastogenesis and bone mass (Bodine and Komm, 2006; 
Krishnan et al., 2006; Piters et al., 2008; Macsai et al., 2008). This concept originated 
when the gain- and loss-of-function mutations of LRP5 were shown to increase and 
decrease bone mass, respectively, in human genetic studies (Boyden et al., 2002; Gong 
et al., 2001). MSCs and osteoblasts express Wnts and other components of the pathway 
suggesting these cells are able to respond to and transmit the Wnt signal. There is 
evidence that human osteoblasts express multiple Frizzled receptor subtypes, and both 
LRP5 and LRP6 co-receptors, though in osteoclasts, only LRP6 has been identified, and 
Wnt3A treatment affected neither osteoclast formation nor activity (Spencer et al., 
2006). On the other hand, mature osteoclasts do express β-catenin and APC (Monaghan 
et al., 2001). Furthermore, the actual source of Wnts in the bone environment is still 
poorly known, but in addition to putative secretion by osteoblasts, the ligands could also 
be released from the extracellular matrix. Specific Wnt ligands involved in the skeletal 
development and bone remodelling are not unequivocal, but at least Wnt3A and 
Wnt10b seem to be ligands important for the osteogenic decision (Boland et al., 2004; 
Bennett et al., 2005). The role of each separate molecule in the pathway and the 
extracellular inhibitors in bone have been widely studied (Liu et al., 2008b; Glass and 
Karsenty, 2006; Pinzone et al., 2009), but this thesis section will focus mainly on the 
Wnt pathway in general, and on the specific role of β-catenin, in particular. 
The expression level of β-catenin is an important factor for the choice of MSC 
commitment. For example, decision between chondrogenic and osteogenic lineage 
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commitment is, at least in part but clearly, controlled by the expression of β-catenin 
(Zhou et al., 2008; Day et al., 2005; Hill et al., 2005); An adequate amount of active    
β-catenin is required for osteogenic commitment, while its level needs to be low for 
differentiation into the chondrocyte lineage. Chondrogenic transcription factor Sox9 
interacts with β-catenin, and increases its degradation thus downregulating Wnt 
signalling and allowing chondrogenic differentiation to proceed (Akiyama et al., 2004). 
The induction of Wnt target gene Twist1 also inhibits chondrogenesis (Reinhold et al., 
2006). Furthermore, adipogenesis is the hypothesized default pathway for MSCs unless 
some inductive signal is present. Wnt/β-catenin signalling inhibits adipogenesis by 
blocking the expression of adipocyte specific marker proteins PPAR-γ and CCAAT 
enhancer binding protein α (Kang et al., 2007), and direct the commitment to 
osteogenesis. More wildly, downregulation of Wnt signalling has even been suggested 
to promote MSCs to differentiate into hepatocytes (Ke et al., 2008), although this trans-
differentiation is still debatable. Nevertheless, β-catenin is recognized as being the key 
regulator of osteoblastogenesis. 
In addition to the early stages of commitment, expression of β-catenin seems to be 
crucial also for the subsequent differentiation of osteoblasts and for properly formed 
bone. Msx2 is at least one of the characterized transcription factors activating skeletal 
Wnt signalling (Cheng et al., 2008). Wnt signalling has been observed especially at 
areas of bone formation in vivo in a reporter mouse model (Hens et al., 2005), while    
β-catenin conditional knockout mice showed lack of bone, although cartilage was 
formed and ALP as well as type I collagen produced (Hu et al., 2005). Wnt signalling 
directly stimulates Cbfa1 expression and its target gene OCN in vivo (Gaur et al., 2005), 
although also an opposite result has been reported earlier in mouse osteoblastic cells 
(Kahler and Westendorf, 2003). The Wnt pathway mediates the effects of BMP-2 in 
inducing bone formation (Chen et al., 2007a). In addition, increased osteoblastic 
lifespan has been observed as Wnt signalling has been shown to inhibit apoptosis of 
osteoblast progenitors and differentiated cells (Almeida et al., 2005), and sFRPs are 
reported to be central modulators of osteoblast and osteocyte survival since their 
expression level is linked to cell death (Bodine et al., 2005). However, in the later stage 
of osteoblast differentiation and mineralization, the suppression of Wnt pathway has 
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been found to be necessary (de Boer et al., 2004; Li et al., 2005; Vaes et al., 2005). 
Osteocytes, for example, were shown to express Sclerostin (ten Dijke et al., 2008), 
osteoblasts were reported to upregulate sFRP and WIF-1 expression (Vaes et al., 2005), 
whereas Lef-1 was undetectable in fully differentiated osteoblasts (Kahler et al., 2006). 
There are, however, fewer studies on the effects of Wnt signalling in osteoclasts. These 
are mainly reports about indirect effects via regulation of the RANKL-OPG pathway by 
the osteoblasts leaving the possible direct effect yet unknown. Active Wnt signalling 
has been shown to induce osteoblastic expression of OPG (Glass et al., 2005) and 
decrease RANKL production (Spencer et al., 2006). In summary, Wnt pathway affects 
positively bone formation via at least two mechanisms: by stimulating osteoblast 
commitment, activity, and lifespan as well as by inhibiting bone resorption and 
adipocyte differentiation. The effects seem to depend, however, on the differentiation 
stage of the cells (Eijken et al., 2008).  
Additional players involved in the regulation of Wnt pathway in bone emerge all 
the time. A growth factor R-spondin1, synergistically with Wnt ligand, stimulates 
osteoblast differentiation, and is thus designated as a Wnt agonist (Lu et al., 2008). 
OSTM1 (osteopetrosis-associated transmembrane protein 1) regulates the                     
β-catenin/Lef-1 interaction and thus favours Wnt signalling (Feigin and Malbon, 2008). 
Expression of Wdr5, a WD repeat protein and a marker for actively transcribed genes, 
positively regulates the Wnt pathway and is essential for osteoblast differentiation (Zhu 
et al., 2008). On the other hand, LIM protein Limd1 and DIFs (differentiation inducing 
factors) have recently been characterized as being negative regulators of Wnt signalling 
in osteoblasts by increasing β-catenin degradation and suppressing its expression, 
respectively (Matsuzaki et al., 2006; Luderer et al., 2008). Although being an 
osteoblast-specific transcription factor, Osterix has been reported to inhibit Wnt 
signalling via induction of Dkk-1 and by binding TCF-4 (Zhang et al., 2008a) indicating 
an even more complex regulation of the optimal bone cell function through the Wnt 
signalling pathway. 
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2.4 Glutamate signalling and bone 
 
2.4.1 Glutamate as a neurotransmitter 
 
The amino acid L-glutamate is the predominant excitatory neurotransmitter in the 
mammalian central nervous system (CNS). Glutamatergic transmission is believed to be 
involved in several important brain functions, such as learning and memory (Bliss and 
Collingridge, 1993). At high concentrations, glutamate may act as a potent endogenous 
neurotoxin and this so-called excitotoxicity appears to be involved in the pathogenesis 
of many neurodegenerative disorders (Meldrum, 1998). Alternatively, an excessive 
uptake of glutamate may result in glutamatergic hypofunction. Therefore, precise 
control of the amount of glutamate is important for the maintenance of optimal 
extracellular glutamate levels to avoid any inappropriate consequences. 
The signalling events can be divided into three phases: initiation, propagation, and 
termination. Glutamate is synthesized and stored in specialized glutamatergic neurons. 
Activation of the pre-synaptic neuron leads to calcium-dependent glutamate release into 
the synapse. The released glutamate activates several classes of glutamate receptors 
(GluRs) on the post-synaptic membrane. GluRs are divided into two groups according 
to their differential intracellular signal transduction mechanisms: ionotropic ligand-
gated ion channels (iGluR) and G-protein-coupled metabotropic receptors (mGluR). 
These subclasses can be further divided into distinct subtypes according to their 
sensitivity to pharmacological ligands. (Dingledine et al., 1999) The glutamate signal is 
terminated by the activities of high affinity glutamate transporters located at the plasma 
membranes of the surrounding cells. These transporters rapidly take up glutamate from 
the synapse and transport it back into the cells. This mechanism works against a several 
thousand-fold concentration gradient and is thus able to ensure that the glutamate 
concentration in the synaptic cleft remains below the level that activates receptors. Five 
separate glutamate transporters have been characterized in rodent and human brain: 
glutamate/aspartate transporter 1, i.e., excitatory amino acid transporter 1         
(GLAST-1/EAAT-1), glutamate transporter-1 (GLT-1/EAAT-2), and EAAT-3, EAAT-
4, as well as EAAT-5 (Seal and Amara, 1999; Danbolt 2001).  
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2.4.2 Identification of the key players in bone 
 
Glutamate signalling has also been characterized outside the CNS. Functional 
glutamate receptors have been observed in adrenal gland (Yoneda and Ogita, 1986), 
pancreas (Inagaki et al., 1995), lung (Said et al., 2001), some regions of gut (Shannon 
and Sawyer, 1989), megakaryocytes (Genever et al., 1999a), and keratinocytes 
(Genever et al., 1999b). The first clue of glutamate signalling in the bone environment 
emerged from experiments with gene screening assays aiming to identify novel genes 
involved in the regulation of bone mass (Mason et al., 1997). In that study, rat 
osteocytes were found to respond to mechanical loading by downregulating the 
expression of glutamate transporters previously localized only in the CNS. Later, also 
other components of the glutamate signalling system have been identified in bone cells. 
The cellular origin of glutamate and the mechanisms leading to its release from 
bone are not fully understood, but several putative mechanisms have been proposed. 
Osteoblasts release actively glutamate into the extracellular matrix both spontaneously 
and in a regulated manner. Osteoblasts possess similar machinery for regulated 
vesicular glutamate exocytosis as is present in presynaptic neurons: osteoblasts express 
exocytotic 'SNARE' proteins, i.e., SNAP and NSF attachment receptors, which mediate 
the fusion of cellular transport vesicles with cell membranes. Also synaptotagmin I, 
specialized for fast calcium-dependent exocytosis, is expressed in osteoblasts. (Bhangu 
et al., 2001) Glutamate can be released from the cells by modulating electrochemical 
gradients not related to exocytosis, too (Mason et al., 1997). Furthermore, bone is 
innervated and nerve fibers containing glutamate have been detected in this tissue, in the 
vicinity of bone cells (Serre et al., 1999). In addition, many bone proteins are rich in 
glutamate which is then released upon protein catabolism during resorption and could 
thus contribute to the signalling competent pool of glutamate (Spencer et al., 2007).  
In order to be able to receive the signal, all bone cells (osteoblasts, osteoclasts, and 
osteocytes) have been reported to express GluRs, mainly iGluRs but osteoblasts also 
mGluRs (Chenu et al., 1998; Patton et al., 1998; Espinosa et al., 1999; Gu and 
Publicover, 2000; Itzstein et al., 2001). The iGluRs can be divided into N-methyl-D-
aspartic acid (NMDA), AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
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acid), and kainate receptors from which the NMDA receptors (NMDAR) have been 
most widely studied in terms of osteoblast function (Spencer et al., 2007). Activation of 
these receptors at the cell membrane leads to inward current of calcium ions, and this 
influx is mainly responsible for mediating the effects of glutamate by converting the 
electrical signals into biochemical responses controlling various cellular actions. For 
example, calcium-dependent enzymes, e.g., many kinases (calcium/calmodulin- 
dependent protein kinase II, tyrosine kinase, and protein kinase C), and phosphatases 
are affected by the receptor activation. Functional NMDARs are multimeric complexes, 
and the osseus cells express several different subunits and splice variants, revealed by 
reverse transcriptase polymerase chain reaction (RT-PCR), in situ hybridization, and 
immunohistochemistry, suggesting a high molecular diversity of NMDA channels 
similar to what was found in brain (Itzstein et al., 2001). For example, human 
osteoblastic MG-63 cells express mRNA for NMDAR subunits NR1, NR2A, NR2B, 
and NR2D as well as NR3A, but not for NR2C or NR3B. In addition, these cells have 
been shown to express EAAT-1, mGluR1, mGluR2, mGluR3, mGluR4, mGluR5, and 
mGluR8, but not mGluR6 or mGluR7. (Kalariti et al., 2004)  
The main goal of glutamate transporters is to prevent signal overdose, and to 
provide molecules to be re-released. They act to enhance the signal-to-noise ratio of 
glutamate so that the transmitter could be perceived from a background of millimolar 
glutamate concentrations. First, GLAST-1 was characterized in osteocytes, and later 
also in osteoblasts (Mason et al., 1997), but interestingly not in osteoclasts (Skerry, 
1999). GLAST-1 is localized in the plasma membrane consistent with its glutamate 
uptake function. Also a splice variant (GLAST-1a) lacking the third exon has been 
identified in osteoblasts (Huggett et al., 2000). This variant may differ in its subcellular 
distribution, and may respond differently to variable glutamate concentrations (Huggett 
et al., 2002). Interestingly, GLAST-1a might possess even a reversed orientation at the 
membrane and transport of glutamate could thus be inverted. Transcriptional regulation 
and post-translational modification of GLAST isoforms may therefore provide 
additional regulation of glutamate signalling in bone. According to brain studies, 
function of GLAST-1 could also be modified by phosphorylation and regulate 
trafficking via the transporter (Conradt and Stoffel, 1997), but corresponding studies in 
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bone have not been published. Another transporter, GLT-1, has been identified in the 
marrow cells, but not in osteoblasts or osteocytes (Mason et al., 1997). Recently, also 
EAAT-2 and EAAT-3 have been characterized in osteoblasts (Takarada et al., 2004). 
An additional intracellular vesicular transporter (VGLUT) has been found in osteoblasts 
and osteoclasts, the function of which is to actively import glutamate into the secretory 
vesicles (Hinoi et al., 2002). 
 
 
2.4.3 Function in bone 
 
Although many essential molecules involved in glutamate signalling have been 
identified in bone, the functionality of this pathway has been less studied in the skeletal 
cells, so far. NMDAR activity is apparently important for Cbfa1 expression in 
osteoblasts since inhibition of the receptor activity leads to marked inhibition of Cbfa1 
mRNA and protein expression as well as decreased DNA binding activity thus 
preventing osteoblast differentiation. (Hinoi et al., 2003) Blockade of NMDARs with 
antagonists like dizocilpine (MK801), has been shown to inhibit expression of two 
osteoblastic markers, ALP and OCN, and also impair matrix mineralization possibly via 
regulation of Cbfa1, in particular. In addition, glutamate signalling appears to regulate 
osteoblast proliferation and survival, and the inhibition of glutamate release with 
riluzole was reported to compromise cell viability (Genever and Skerry, 2001). 
Glutamate receptor function, GLAST expression, and glutamate release also vary with 
the differentiation status of the osteoblasts under study, and these cells gain more active 
glutamatergic phenotype in conjunction with differentiation (Genever and Skerry, 2001; 
Hinoi et al., 2002). During osteoblast maturation, glutamate release corresponded to 
increased ALP activity (Bhangu et al., 2001). Glutamate release, however, reaches a 
plateau before complete depletion of the intracellular glutamate stores (Bhangu et al., 
2001).  
Osteoclasts are also responsive to glutamate, and exhibit a glutamatergic phenotype 
upon differentiation (Peet et al., 1999; Itzstein et al., 2001; Merle et al. 2003). In 
addition to bone formation, regulation of extracellular glutamate may also influence 
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resorption activity. This raises the question of intercellular communication and the role 
of glutamate in this phenomenon (Fig. 10.). Osteoclastogenesis is highly dependent on 
constitutive glutamate signalling as MK801 modulates bone resorption in vitro (Peet et 
al., 1999). It is, however, possible that the effects of glutamate on osteoclastogenesis are 
mediated indirectly through osteoblasts, but mature osteoclasts do contain these 
VGLUTs, and are thus able to secrete glutamate, at least. Despite all this data and 
important features characterized in vitro, a clear physiological indication of glutamate 
signalling in bone still awaits to be demonstrated. In most experimental cases, glutamate 
receptor deficiency is lethal or neurologically severe, and glutamate transporter knock-
out animals have not provided final confirmation since no major skeletal abnormalities 
were reported (Gray et al., 2001). VGLUT deficient mice, however, do develop 
osteoporosis (Hinoi et al., 2002).  
 
 
 
Fig. 10.  Summary of the effects of glutamate signalling on intercellular communication, bone 
cell function, and bone remodelling. NMDA = N-methyl-D-aspartic acid; AMPA = α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid; KA = kainate; mGluR = metabotropic glutamate 
receptor; EAAT = excitatory amino acid transporter; VGLUT = vesicular glutamate transporter; 
VOCC = voltage gated calcium channel. (Reprinted from Spencer et al., 2007, with kind 
permission of Elsevier.) 
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2.5 Cross-talk between signalling pathways 
 
Cells are bombarded with multiple extra- and intracellular signals, and need to 
decide how to act accordingly. These messages launch biochemical reactions leading to 
diverse cellular events, which are necessary for the cells to adapt their responses to the 
constantly changing conditions. Although many independent signalling cascades guide 
cellular function, also cross-talk between distinct pathways is now well recognized as 
one critical regulatory mechanism. This complex control mode provides nearly 
unlimited possibilities to alter cell´s properties, activities, and functions. Cross-talk 
mechanisms can involve different molecules, e.g., receptors, second messengers, and 
kinases, and can occur between similar pathways, such as those originating from the 
membranes, or communication between membrane and intracellular signalling 
pathways as well. Furthermore, these interactions do not necessarily occur in the same 
cellular compartment or even in the same cell. Depending on the relative strengths of 
the signals in question, the specificity of signalling can be tuned to prevent some 
interactions from occurring across pathways while allowing others. The appropriate 
level and optimal activity of the regulator molecules are a prerequisite for proper 
cellular function and determine whether opposing or synergistic effects will prevail. 
Altered protein expression, variable post-translational modifications, high-fidelity 
protein-protein interactions as well as stability and subcellular localization of the 
signalling members or regulatory molecules are key mechanisms for the cross-talk 
processes. The specificity of the interplay can be quaranteed, for instance, by separating 
closely related systems from one another or by linking them tightly in either temporal 
manner, by different developmental stages, or in space, by chaperones as well as 
compartmentalization within the cell, for example.  
In the bone environment, cross-talk between various signalling pathways affecting 
the osteogenic commitment process and different maturational stages of the osteoblasts 
has also recently been reported. To mention few, BMP-2 signalling is able to control 
ALP expression and osteoblast mineralization by affecting Wnt signalling (Rawadi et 
al., 2003), and also the PTH/cAMP/protein kinase A signalling pathway has been 
shown to facilitate the Wnt cascade in osteoblastic cells (Kulkarni et al., 2005; Suzuki et 
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al., 2008). In addition, IGF-I and FGF cascades exhibit cross-regulation in the control of 
AKT (protein kinase B) and ERK (extracellular signal-regulated protein kinase) 
pathways in osteoblasts, respectively (Raucci et al., 2008). Interleukin-6 and 
prostaglandin E2 signalling systems have been reported to interact in the regulation of 
the OPG/RANK/RANKL system, and thus to influence osteoclast function (Liu et al., 
2005). Also concerning different types of pathways, estrogen and TGF-β pathways have 
been shown to amplify each others actions thus leading to enhanced beneficial function 
in osteoblastic cells (Hawse et al., 2008). Evidence has also been gathered that calcitriol 
and Notch signalling pathways may co-operate in the regulation of OPN expression 
(Shen and Christakos, 2005), and calcitriol signalling also interacts with TGF-β signal 
transduction in the control of OCN production (Subramaniam et al., 2001). At the 
nuclear level, cross-talk between GC and calcitriol signals has been described in the 
control of OCN production (Aslam et al., 1995). Therefore, multiple pathways can 
directly or indirectly control the balanced activity of osteoblasts, and thereby be able to 
change the physiological milieu in bone. The key question is, how the osteoblast - or 
any cell, for that matter - ensures, that a given signal reproducibly leads to an 
appropriate response rather than provoking an irrelevant reaction within this complex 
network of incoming messages.  
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3. AIMS OF THE STUDY 
 
GCs are known to have both beneficial as well as detrimental effects on osteoblasts 
and on bone health. They are required for osteopoiesis, but during osteogenesis, their 
harmful effects may finally lead to osteoporosis, especially with pharmacologically 
relevant dosages used to treat many diseases. Due to this complexity, the molecular 
mechanisms behind these events are still not fully known. Therefore, a better 
comprehension of these mechanisms would be beneficial in the development of new 
treatments for retaining the advantageous features while eliminating the deleterious 
properties of these steroids.  
The experiments presented in this thesis were designed to elucidate the molecular 
mechanisms of GCs involved in controlling osteoblast differentiation and function. The 
cross-talk between the signalling pathways interfering with GC action was examined in 
detail. Clinical applications with therapeutic US were also studied in a cell culture 
system in order to characterize the molecular mechanisms behind the beneficial effects 
observed with this technique on bone healing. 
 
The specific aims of this study were, firstly,  
 to identify novel GC-induced changes in the protein expression profile of human 
osteoblastic cells,  
 to characterize the regulation and function of potential novel GC target genes in 
greater detail, 
 
and secondly, 
 to examine the mechanisms involved in the cross-talk between GC and Wnt 
signalling pathways, and 
 to analyze the effects of therapeutic US on the activity of Wnt signalling 
pathway.  
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4. MATERIALS AND METHODS 
 
4.1 Cell culture 
 
4.1.1 Clonal cell lines 
 
Human osteoblast-like osteosarcoma cells, MG-63, U2Os, SaOs-2, and G-292, were 
obtained from the American Type Culture Collection. All the cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM, Gibco BRL) supplemented with        
7% fetal bovine serum (FBS, Gibco BRL or HyClone), 2 mM L-glutamine, 100 U/ml 
penicillin, and 0.1 mg/ml streptomycin at 37°C in a humidified atmosphere of 5% CO2 
in air. The experiments were performed in medium containing 2% charcoal-treated FBS 
to eliminate the effects of endogenous steroids. The hormones, ligands, or other 
compounds of interest were dissolved in H2O, ethanol, or DMSO (dimethyl sulfoxide), 
and the control cultures contained the same amount of corresponding solvent(s).  
 
 
4.1.2 Conditionally immortalized osteoblasts 
 
Conditionally immortalized human HOB cells (preosteoblasts HOB-03-C5 and 
mature osteoblasts HOB-03-CE6) were generously provided by Dr P. Bodine from 
Wyeth Research, USA. Experiments with these cells were conducted according to 
previous publications (Bodine et al., 1997 and 1999). The cells are immortalized with a 
temperature-sensitive SV40 large T antigen. Therefore, these cells express a 
transformed phenotype at the permissive temperature of 34°C but revert to a normal 
phenotype at the non-permissive temperature of 39°C, usually when cultured for 48 h. 
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4.1.3 Bone marrow stromal cell derived osteoblasts 
 
Osteoblasts were also induced from rat MSCs. Femurs of 9 to 10-week-old male 
Wistar rats were excised aseptically, cleaned from adhering soft tissues, ends of bones 
were cut, and the bone marrow was flushed out with a 22-gauge needle and culture 
medium. The cells were centrifuged and resuspended in the medium. The single cell 
suspension was plated in T25 tissue culture flasks at a density of 106 cells/cm2. The 
culture medium was phenol red-free α-MEM (α-Minimal Essential Medium) with    
10% FBS (Gibco BRL), 20 mM HEPES, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 
and the osteogenic supplements 10 nM Dex, 50 μg/ml L-ascorbic acid phosphate, and 
10 mM sodium β-glycerophosphate. At day 3, the non-adherent cells were discarded by 
a medium change. The selection of MSCs is based on plastic adherence only, and 
therefore cultures could be heterogeneous in nature and may contain some 
hematopoietic cells as well. After the total 7 day primary culture period, a subculture 
was prepared by trypsinizing the cells and seeding them into 24-well plates or 6 cm 
dishes at a cell density of 5000 cells/cm2, either with or without the osteogenic 
supplements and tested compounds. These experiments were approved by the 
Experimental Animal Committee of the University of Kuopio, Finland. 
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4.2 Gene transfers 
 
4.2.1 DNA constructs 
 
TABLE 1. The plasmid constructs used in this thesis work.  
PLASMID INSERT TYPE SOURCE 
 
TOPflash 
 
two sets of three TCF binding sites 
 
reporter 
 
Upstate 
 
FOPflash one mutated TCF binding site reporter Upstate 
 
pGL3-MMTV(-1146/+88)-
Luc 
region containing multiple GREs reporter Dr J. Palvimoa 
    
pcDNA3.1-flag-β-catenin human full length β-catenin expression Dr HC. Cleversb
 
pcDNA3.1-flag- S33Y-β-
catenin 
 
point mutant Ser-33 → Tyr in βCAT 
 
expression Dr HC. Cleversb 
pcDNA3.1-flag-
S33Y/Y654A-β-catenin 
point mutant Ser-33 → Tyr & point 
mutant Tyr-654 → Ala in βCAT 
 
expression A. Olkku 
pCMV6-XL5-hCRT human full length calreticulin expression Origene 
 
pCMV-β-galactosidase β-galactosidase expression Clontech 
 
pSG5-hGR human full length GR expression Dr J. Palvimoa
 
pSG5-hGR(K442A) 
 
pSG5-hGR(V443A) 
 
point mutant Lys-442 → Ala in hGR 
 
point mutant Val-443 → Ala in hGR 
 
 
expression 
 
expression 
 
A. Olkku 
 
A. Olkku 
pSG5-hGR(F444A) point mutant Phe-444 → Ala in hGR 
 
expression A. Olkku 
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Table 1 continues 
 
pSG5-hGR(F445A) 
 
 
 
point mutant Phe-445 → Ala in hGR 
 
 
 
 
expression 
 
 
 
A. Olkku 
pSG5-hGR(K446A) point mutant Lys-446 → Ala in hGR 
 
expression A. Olkku 
pSG5-hGR(R447A) point mutant Arg-447 → Ala in hGR 
 
expression A. Olkku 
pSG5-hGR(F444A/F445A) double mutant Phe-444 → Ala & Phe-
445 → Ala in hGR 
expression A. Olkku 
 
pEGFP-hGR(1-777) 
 
human full length GR 
 
expression 
 
Dr J. Zilliacusc 
    
pEGFP-hGR(418-503) DBD region of hGR expression Dr J. Zilliacusc
 
pEGFP-hGR(485-777) LBD region of hGR expression Dr J. Zilliacusc
 
pEGFP-hGR(418-777) DBD+LBD regions of hGR expression Dr J. Zilliacusc
 
pMT-hGR human full length GR expression Dr S. Okretc 
 
pMT-hGR(415-777) 
 
LBD region of hGR expression Dr S. Okretc 
pMT-hGR(1-77/262-500) N-terminal part of hGR including 
DBD, but lacking AF-1 
expression Dr S. Okretc 
 
a University of Kuopio, Finland 
b Hubrecht Laboratory, Center for Biomedical Genetics, the Netherlands 
c Karolinska Institutet, Sweden 
 
 
The point mutants of pSG5-hGR, i.e., Lys-442 → Ala, Val-443 → Ala , Phe-444 → 
Ala, Phe-445 → Ala, Lys-446 → Ala, and Arg-447 → Ala, double mutant Phe-444 → 
Ala & Phe-445 → Ala, and also double mutant S33Y-β-catenin Tyr-654 → Ala, were 
all obtained by using the Quick-Change™ II XL Site-Directed Mutagenesis kit 
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(Stratagene) according to the manufacturer's instructions. All the mutated sites were 
verified by automated sequencing. 
 
 
4.2.2 Transfections 
 
MG-63 and U2Os cells were used for transient transfections with FuGENE 6 or HD 
lipofection reagents (Roche Diagnostics) according to the manufacturer's instructions. 
MG-63 cells required larger DNA amounts, though. Briefly, the cells were seeded in  
24-well or 6-well plates and grown overnight. The medium was replaced with 
transfection medium (DMEM, 2% charcoal treated FBS, 2 mM L-glutamine) 4 h before 
transfection. On the following day, cells were treated with tested compounds and 
cultured for a specified time. 
In order to silence human calreticulin (CRT) expression in U2Os cells, the cells 
were cultured in 6-well plates, and transfected with CRT siRNA (25 nM, Qiagen, target 
sequence from Harada et al., 2006) or negative control siRNA                            
(5'-AATTCTCCGAACGTGTCACGT-3', Qiagen) using Lipofectamine™2000 
(Invitrogen) according to the manufacturer's instructions. The cells were split after 3-4 
days and retransfected. This was repeated once more, and the plasmid DNAs were co-
transfected along this final siRNA transfection. Reporter assays as well as specific 
endogenous target gene expression were evaluated. The efficiency of the specific 
silencing of CRT was monitored at the protein level with Western blot. 
 
 
4.2.3 Luciferase reporter gene assays 
 
In the reporter assays, firefly luciferase activities were measured 24 h after 
treatments with the Luciferase Assay System (Promega). Luciferase values were 
adjusted for the β-galactosidase activity as previously described (Poukka et al., 1999) or 
total protein content of the corresponding well. The protein concentrations were 
measured with a Bradford assay (Bio-Rad). 
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4.3 Quantitative RT-PCR 
 
Total cellular RNA was isolated by TriReagent (Sigma) or RNA Isolation Kit II 
(Omega Bio-Tek) according to the manufacturer’s instructions. DNase-treated total 
RNA (0.5 - 1 µg) was reverse transcribed by using MuLV reverse transcriptase (MBI 
Fermentas Inc.) and oligo16dT primer. First, RNA was denatured at 65°C for 5 min 
followed by cDNA (complementary DNA) synthesis at 37°C for 1 h. The reaction was 
stopped at 70°C for 8 min. Relative transcript levels were measured mainly by 
quantitative RT-PCR (qRT-PCR) on 96-well plates using the Stratagene MX3000P 
system following the recommended protocol for SYBR Green (a few experiments were 
run with the conventional PCR and quantified by ALFexpress DNA Analysing System 
(Amersham Biosciences) prior to the availability of the qRT-PCR system). The 
reactions were performed with primer pairs for human glutamine synthetase (GS; Wang 
et al., 1996), and CRT (Spence, et al., 2006). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH; Ryhänen et al., 1997) was used as an amplification control 
and the results were normalized against that expression. The PCR cycling conditions 
were: 30-36 cycles of 1 min at 95°C, 45 s at 55-60°C, and 45 s at 72°C. Fold inductions 
were calculated using the formula 2−(ΔΔCt), where ΔΔCt is ΔCt(treatment)−ΔCt(vehicle), ΔCt is 
Ct(gene of interest)−Ct(GAPDH), and Ct is the cycle at which the threshold is crossed. The 
amplification efficiency was controlled and taken into account when necessary. PCR 
product quality was monitored using post-PCR melting curve analysis. 
 
 
4.4 Protein analyses  
 
4.4.1 Proteomics  
 
The cells were lysed in buffer containing 9.8 M urea, 2% CHAPS, 100 mM 
dithiothreitol, and 0.2% Bio-Lytes 3/10 (Bio-Rad). The protein concentration was 
determined using a Bradford assay. Two-dimensional gel electrophoresis (2DE) was 
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performed essentially according to O’Farrell (O´Farrell, 1975) using Bio-Rad Protean 
Isoelectric Focusing Cell and 17 cm immobilized pH gradient ReadyStrips (pH 5–8). 
For the first dimension separation, the protein samples (20-100 µg) were introduced to 
the strips by passive rehydration with rehydration buffer [9.8 M urea, 2% CHAPS,      
15 mM dithiothreitol, 0.2% Bio-Lytes 3/10, trace of bromophenol blue] during 
overnight incubation. Isoelectric focusing was conducted for a total of about 85000 Vh. 
The second dimension separation was a standard sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the gels were 
silver stained with a mass spectrometry-compatible method, and analyzed with visual 
screening. The interesting protein spots were excised and in-gel digested with modified 
trypsin. All mass spectra were obtained by using a MALDI-TOF MS (Matrix-Assisted 
Laser Desorption/Ionization Time-Of-Flight mass spectrometer, Bruker-Franzen 
Analytik). The resulting peptide masses were analyzed with PeptIdent (ExPASy 
Molecular Biology Server) and Mascot peptide mass fingerprint programmes (Matrix 
Science Ltd.). 
 
 
4.4.2 Western blot 
 
Cells for total protein extraction were lysed in TXM buffer [10 mM Tris-HCl       
(pH 7.4), 1 mM MgCl2, 20 µM ZnCl2, 0.02% NaN3, 0.1% Triton X-100], and sonicated 
on ice for 2x 20 s. The lysate was centrifuged and the protein concentration of the clear 
supernatant was determined using a Bradford assay. Equal amounts of protein extracts 
(5-50 µg) were separated on SDS-PAGE, and the proteins were electrotransferred to 
PVDF (polyvinylidene difluoride, Boehringer Mannheim Gmbl) or nitrocellulose 
(Thermo Labsystems) membranes. The proteins under study were immunodetected by 
using antibodies to human GS, β-catenin, GR, Bax, Bcl2, CRT (Santa Cruz 
Biotechnology Inc.), phospho-β-catenin, or phospho-GSK3β (Cell Signalling 
Technology). Equal loading was controlled by using α-tubulin antibody (Santa Cruz). 
The secondary antibodies were conjugated with ALP or HRP (horse radish peroxidase), 
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and the protein patterns were detected either with NBT/BCIP (nitroblue tetrazolium/    
5-bromo-4-chloro-3-indolyl phosphate, Sigma) or ECL (enhanced chemiluminescence) 
technique (Pierce), respectively. 
 
 
4.4.3 Co-immunoprecipitation 
 
The cells were solubilized in RIPA buffer [50 mM Tris-HCl (pH 7.8), 150 mM 
NaCl, 15 mM MgCl2, 5 mM EDTA, 0.5% Triton X-100, 1 mM DTT, protease inhibitor 
cocktail (Sigma)], and the lysates were clarified by centrifugation. After pre-clearing 
with protein G agarose beads (Upstate), the cell lysates were incubated with anti-β-
catenin antibody at 4°C overnight with shaking. The immunocomplexes were captured 
by incubation with protein G beads at 4°C for 2 h. After washing once with RIPA and 
twice with phosphate-buffered saline (PBS), the beads were resuspended in 2x Lammli 
sample buffer and boiled. SDS-PAGE and immunoblotting were performed as described 
above with anti-GR and anti-β-catenin antibodies. 
 
 
4.4.4 Immunofluorescent staining 
 
Cells grown on glass coverslips were washed in PBS and fixed with                      
3% paraformaldehyde in PBS. The plasma membranes were permeabilized in PBS 
containing 0.1% Triton X-100. Coverslips were incubated in a blocking buffer          
(1% bovine serum albumin in PBS) before incubating with the primary antibody, anti-β-
catenin (Santa Cruz). Secondary antibody was FITC-conjugated (fluorescein 
isothiocyanate, Vector Laboratories). Coverslips were mounted with Vectashield 
(Vector Laboratories), and examined by using a confocal laser scanning microscope 
(Nikon® Eclipse TE 300, Nikon Inc.) equipped with UltraVIEW Confocal Imaging 
System (PerkinElmer Inc.). 
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4.4.5 Alkaline phosphatase activity 
 
The cellular ALP activity was determined with the procedure described by Murray 
and co-workers (Murray et al., 1987). The cells were lysed into TXM buffer, and 
sonicated 2x 20 s on ice. Enzyme activity was assayed by measuring the release of       
p-nitrophenol from p-nitrophenylphosphate at 37°C in a buffered solution. The 
absorbances of triplicate samples were measured at 410 nm with Ultrospec 2100 pro 
spectrophotometer (GE Healthcare). The total protein content was analyzed from the 
same samples with a Bradford assay. Specific ALP activity is expressed as 
µmol/min/mg of total protein. 
 
 
4.4.6 Glutamine synthetase activity 
 
GS activity was assayed according to the colorimetric method of Santoro and co-
workers (Santoro et al., 2001) with slight modifications. In this assay, the glutamyl 
transferase activity of GS is exploited: L-glutamine is converted to the corresponding   
γ-glutamylhydroxamate in the presence of hydroxylamine. Briefly, the cells were 
transferred into tubes, lysed in 50 mM imidazole (pH 6.8), and sonicated on ice for      
2x 20 s. One volume of GS assay buffer [50 mM imidazole (pH 6.8), 25 mM arsenic 
acid, 0.16 mM ADP, 50 mM L-glutamine, 2 mM MnCl2, 25 mM hydroxylamine] was 
added, and the samples were incubated at 37°C for 30 min. The reactions were stopped 
with    2 vol of ferric chloride stop solution [2.42% ferric chloride, 1.45% trichloroacetic 
acid, and 1.82% HCl], and the absorbances of triplicate samples were measured at     
540 nm with Multiscan Ex microplate reader (Thermo Labsystems). The total protein 
content was analyzed from the same samples with a Bradford assay. Specific GS 
activity is expressed as nmol/min/mg of total protein.  
To measure the intracellular glutamate concentration, the cells were lysed in TXM 
buffer and sonicated on ice for 2x 20 s. The intracellular glutamate concentration was 
measured by a colorimetric method for determination of L-glutamic acid according to 
the manufacturer´s instructions (Boehringer Mannheim/R-Biopharm). The protein 
59 
 
 
concentrations were measured with a Bradford assay, and the amount of intracellular 
glutamate is shown as nmol glutamate/mg of total protein.  
 
 
4.4.7 Osteocalcin quantitation  
 
The secreted OCN levels were measured from the collected culture medium by an 
IRMA (immunoradiometric) assay according to the manufacturer´s instructions 
(Immunotopics). The radioactivities that were bound to OCN were measured with a 
gamma-counter (1261 Multigamma, LKB Wallac) from the triplicate samples. The 
amount of secreted OCN was adjusted for the total protein measured from the 
corresponding well by a Bradford assay, and expressed as ng OCN/mg of total protein.  
 
 
4.5 Cell viability assays 
 
4.5.1 Nuclear fragmentation 
 
Morphological assessment of apoptotic cells was performed by using Hoechst 
staining. Cells grown on glass coverslips were washed in PBS and fixed with             
3% paraformaldehyde in PBS. Cells were permeabilized in PBS containing              
0.1% Triton X-100, and nuclei were stained with Hoechst 33258 dye (10 µg/ml, Sigma), 
and potential nuclear fragmentation was observed with fluorescence microscopy 
(Nikon® FXA Microphot, Nikon Inc.). 
 
 
4.5.2 Live/Dead staining 
 
Cell viability was assessed with live/dead staining by using fluorescein diacetate 
(25 μg/ml, Sigma) and propidium iodide (40 μg/ml, Sigma) for detecting viable and 
non-viable cells, respectively (Ruiz et al., 1991). Living cells actively convert non-
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fluorescent fluorescein diacetate into green fluorescent compound, a sign of viability. 
Propidium iodide intercalates in DNA producing red fluorescense in the nucleus of 
membrane-damaged, necrotic cells. The cells were washed once with PBS and stained 
for 10 min. After washing with PBS, each preparation was directly examined with a 
confocal laser scanning microscope. Cell viability was estimated in each well, by 
randomly selecting 100 cells and evaluating the % of live and dead cells.   
 
 
4.5.3 Lactate dehydrogenase activity  
 
Lactate dehydrogenase activity was measured from the collected culture medium 
according to manufacturer´s instructions (Biovision Inc.). The culture medium was 
centrifuged shortly, one part medium and one part assay mixture combined and then 
incubated for 20 min at room temperature in the dark. The absorbances of three 
replicates were measured at 492 nm with Multiscan Ex microplate reader. Triton X-100 
(1%) treatment was used as a 'high control' to evaluate the maximum amount (100%) of 
lactate dehydrogenase released from the cells. The results are calculated as  
cytotoxicity-%.   
 
 
4.5.4 Caspase activity 
 
The activities of caspase-8 and caspase-3, respective early and late markers of 
apoptosis, were characterized from exposed cells with a colorimetric assay (Biovision 
Inc.) according to the manufacturer´s instructions. Assay is based on detection of the 
chromophore p-nitroanilide (pNA) after cleavage from the labeled substrate IETD-pNA 
or DEVD-pNA by caspase-8 or caspase-3, respectively. Absorbances of free pNA were 
quantified by using a microplate reader (Multiskan Ex) at 405 nm, and were adjusted for 
the total protein measured by a Bradford assay. Results are presented as absorbance 
units/mg protein.  
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4.6 Measurement of mineralization 
 
4.6.1 Calcium assay  
 
The cells were washed with PBS, fixed with 3% paraformaldehyde in PBS, and 
incubated in 0.6 M HCl overnight at room temperature with shaking. Calcium 
determination was based on the reaction of calcium with o-cresolphthalein-complexone 
in alkaline solution according to the manufacturer’s instruction (Roche Diagnostics). 
The absorbances of three replicates were measured at 546 nm with Ultrospec 2100 pro 
spectrophotometer. Absolute calcium concentration was determined by using a calcium 
standard provided by the manufacturer. 
 
 
4.6.2 Von Kossa staining 
 
For the visual detection of bone nodules, the cells were washed with PBS, fixed 
with 3% paraformaldehyde in PBS, and stained with the von Kossa method for calcium 
deposition (Bills et al., 1972). The cells were incubated in 2% silver nitrate in front of a 
60-W lamp for 1 h during which the silver replaces the deposited calcium, and rinsed 
three times with distilled water. The final fixation was performed with 2.5% sodium 
thiosulphate.  
 
 
4.7 Ultrasound and hyperthermia experiments  
 
4.7.1 Ultrasound exposures 
 
The US device consists of six air-backed piezoceramic discs (type PZT26, 
Ferroperm Piezoceramics A/S) with a diameter of 25 mm in a poly(methyl 
methacrylate) (PMMA) housing (Fig. 11.). Three of the six transducers with operating 
frequency of 1.035 MHz were used in this study. The electric driving signals to the 
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transducers were generated using function generators (model 33120A, Hewlett-
Packard/Agilent Technologies Inc.) and radio frequency amplifiers (model 240L, 
Electronic Navigation Industries). Each transducer was equipped with 50 Ω impedance 
matching network and driven with separate signal generator-amplifier pair. The acoustic 
power values for each transducer were measured in free-field using an in-house-made 
radiation force balance. The measurements were performed at room temperature using 
continuous wave US and this data was used to calculate suitable acoustic power and 
intensity levels for the exposures. In the experiments, the distance between transducers 
and well bottom was set to 7.7 mm which is in the near field of the transducers. 
Standing wave is formed between the transducer and culture medium-air interface. The 
whole exposure system excluding the 24-well plate holder was fully immersed in a 
water bath. To maintain the humidity and temperature during the sonications, a PMMA 
frame covered with thin aluminum foil was positioned on top of the culture plate. 
 
 
 
 
Fig. 11. Ultrasonic system used in cell sonications and example configuration of the sample 
wells. Linear slides were used to position the transducers directly under the corresponding wells 
in different rows of the plate. PMMA = poly(methyl methacrylate); RO = reverse osmosis. 
(From original publication IV) 
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The temperature of the water tank was maintained at 37 ± < 0.1°C or 30 ± < 0.1°C 
using a controllable mixing thermostat (Grant GP200, Grant Instruments Ltd.). Water 
level was adjusted to reach the bottom of the culture plate so that the acoustic path from 
the transducers to the cells was ensured. The total liquid volume in each well was 
always exactly the same. The US exposure was a 10 min long single exposure. The 
control cells in separate plates were treated identically as the exposed cells omitting the 
US stimulus. The repeatability of the system was monitored with radio frequency power 
measurement system consisting of a power meter and a power sensor (models E4419B 
and 8482H, Hewlett-Packard/Agilent Technologies Inc.) and a dual directional coupler 
(model C2635, Werlatone Inc.).  
 
 
4.7.2 Thermal exposures 
 
The cells were cultured in 24-well plates and heat-treated using stainless steel water 
bath. This water bath was calibrated against controllable mixing thermostat (Grant 
GP200, Grant Instruments Ltd.). To ensure the uniformity of the water inside the bath, 
the water was circulated using an immersion pump. The temperature stability was found 
to be better than 0.1°C. The heat exposure was a 10 min long single exposure, and the 
protocol was identical to the US exposure including the liquid levels, liquid additions, 
duration, and post-exposure procedures.    
 
 
4.7.3 Temperature measurements 
 
The temperature elevations in both the US and thermal exposures were recorded by 
using copper-constantan thermocouples (Omega Engineering Ltd.) connected to a 
digital multimeter (model 2000 with TCSCAN-2001 card, Keithley Instruments Inc.). In 
the US system, the thermocouples were placed parallel relative to the direction of sound 
in the US field. The tip of the temperature probe without Teflon® insulation was put 
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inside the well in contact with the bottom of the plastic at the center of the well. The 
measurements with the heat exposure system were made in a similar fashion. 
To quantify and compare the biothermal effects of US and heat exposure, the 
thermal dose was calculated from the temperature measurements. The concept of dose 
(Sapareto and Dewey, 1984) quantifies the effect of elevated temperature to the target as 
a function of time, and is often referred to as cumulative equivalent minutes at 43°C 
(CEM43). Using this method, thermal doses and their possible tissue-responses of 
dissimilar heating profiles with varying time and temperature values can be 
standardized and compared. In our study, the following generally accepted rules for 
calculating the thermal dose were used  
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The parameter Δt is the time step between the temperature measurements Ti and is in 
our case 1 s.  
 
 
4.8 Statistics 
 
All the experiments were repeated independently two to three times using three 
replicates in the assays. The results are shown as mean ± SD. The statistical 
significances of the differences between groups were analyzed with Student´s t-test or 
ANOVA (one-way analysis of variance) followed by Tukey´s post test by using the 
Excel 2003® (Microsoft Corp.) or GraphPad Prism® (GraphPad Software Inc.) 
programmes. *** p<0.001, ** p<0.01, * p<0.05. 
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5. RESULTS 
The following section presents the main results of each study. Further details are 
presented in the original publications I-IV. 
 
 
5.1 Identification of glucocorticoid target genes (I) 
 
Proteomics is a powerful tool to characterize changes in the protein expression 
profiles of tissues or cells, and can be used to study the effects of test compounds, or 
normal versus pathological conditions. The mRNA levels in the cells do not necessarily 
correlate to protein expression, so information of what proteins and where they are 
expressed, is needed. High-resolution 2DE is a method capable of separating complex 
protein mixtures such as those present in eukaryotic cells: 2DE provides good 
methodology for reproducible separation of thousands of proteins in one gel, although 
other competitive methods have also been designed.  
The aim of our proteomic approach was to identify GC-induced changes in the 
proteome of human osteoblastic cells. MG-63 cells were treated with vehicle or GCs, 
and the protein samples from these cells were separated in 2DE in the pH range 5-8, and 
visualized by silver staining. The gels were compared and the differentially expressed 
proteins were localized by visual screening. One major change was observed in the  
MG-63 cells treated with GCs, and it was identified by mass spectrometry as GS 
(glutamate-ammonia ligase, EC 6.3.1.2) (Fig. 12.). The GC induction of GS was 
confirmed with Western blot as well as the GS enzyme activity assay. This GR-
mediated stimulation was also seen at the transcriptional level, and the induction 
required new protein synthesis. Although GCs have been reported to possess some 
proapoptotic features (Weinstein et al., 1998), GS induction was not directly linked to 
cell death in our experiments.  
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Fig. 12. (A) A two-dimensional, silver-stained gel of protein extracts from human MG-63 cells. 
The inset shows the region of interest that is displayed in panel B. (B) Differentially expressed 
protein pattern after 24 h treatment with GCs. In further studies, the protein designated by the 
arrow was identified to be GS. (From original publication I) 
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GS, an ATP-dependent enzyme catalyzing conversion of glutamate to glutamine 
(Fig. 13.), has a central role in amino acid metabolism and pH regulation in mammals.  
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Fig. 13. The reaction catalyzed by GS. The ATP-dependent reaction proceeds in two steps. 
First, glutamate and ATP react to form ADP and a γ-glutamyl-phosphate intermediate, which 
then reacts further with ammonia leading to the production of glutamine and inorganic 
phosphate.  
 
 
5.2 Regulation of glutamine synthetase (I&II) 
 
5.2.1 Hormonal modulation 
 
GS has already been known to be regulated by GCs in many cells and tissues such 
as chick neural retina, rat hepatoma cells, myoblasts, jejunum, and pituitary glands as 
well as in human leukemic cells and mouse adipocytes (Moscona et al., 1972; Kulka 
and Cohen, 1973; Harmon and Thompson, 1982; Max et al., 1987; Saini et al., 1990; 
Sarantos et al., 1994a; Shirasawa and Yamanouchi, 1999). Our finding of the GC 
control in bone is, however, a novel observation. GS expression and activity were 
induced time- and dose-dependently by GCs in human MG-63 and G-292 osteoblastic 
cells as well as in conditionally immortalized human HOB cells (HOB-03-05 and  
68 
 
 
HOB-CE06), which all express measurable amounts of GR. GC induction of GS was 
very rapid being visible already after a few hours at the protein level. On the other hand, 
in cells basically devoid of GR, i.e., human U2Os and SaOs-2 osteoblastic cells, GS 
activity did not respond to GCs supporting the receptor-mediated response also shown 
with the receptor antagonist mifepristone (RU38486) in our studies. Silencing elements 
for GCs in rodent GS have been identified in the distal 5´-flanking region and in the first 
intron (Hadden et al., 1997; Chandrasekhar et al., 1999), but there are no studies of the 
possible GREs in the human gene, although that would seem rather evident. 
Interestingly, the GC induction required functional proteosome complex, since the 
inhibition of proteosomal degradation activity by MG-132 prevented the induction 
almost completely in MG-63 cells. This might indicate a requirement for degradation of 
a potential silencer molecule, but this is speculative, though. Among other cells as well, 
GS seems to be an essential enzyme for osteoblastic cells, since glutamine deprivation 
and inhibition of the activity by methionine sulphoximine evoked a compensatory 
increase in GS expression in these cells. In addition to GS, the enzyme catalyzing the 
reverse reaction, glutaminase, has been reported to be regulated by GCs in human 
intestinal cells and in lymph nodes (Sarantos et al., 1994b; Dudrick et al., 1993), but we 
were not able to detect any changes in its expression in MG-63 cells with the antiserum 
used (our unpublished observation). 
Based on literature, GS expression can be regulated in a number of ways, for 
example, by tumour necrosis factor α that increases GS activity (Chakrabarti, 1998), 
whereas IGF-I and insulin inhibit GC-induced enzyme action in rat skeletal muscle cells 
and in chick neuronal cells, respectively (Kimura et al., 2001; Tholey et al., 1986). In 
our further studies, other hormones were tested for their ability to regulate GS activity 
in MG-63 cells. Dihydrotestosterone, estradiol, progesterone, triiodothyronine, and 
aldosterone were without any effects, but calcitriol was found as a negative regulator of 
both basal and GC-induced GS expression and activity. Calcitriol showed inhibition at 
the mRNA level as well as increased GS protein degradation. According to our 
knowledge, there are no previous reports about the regulation of GS by calcitriol in any 
tissue. The inhibitory effect of calcitriol was also evident in another cell model, namely 
rat MSCs. Under osteogenic culture conditions, these cells differentiate into osteoblasts 
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as characterized by the presence of specific markers ALP and OCN as well as calcium 
content and mineral deposition, noted also in our experiments. Both GCs and calcitriol 
are important for bone health, and the apparent control of GS by both of these steroids 
highlights the importance of its regulation during osteoblastogenesis.  
 
 
5.2.2 Inhibition by the Wnt pathway  
 
Wnt signalling is known to be important for osteoblast development and function. 
Therefore, we were keen to examine whether it could control GS activity in osteoblastic 
cells. Activation of the Wnt pathway by the canonical ligand Wnt3A, indeed, 
downregulated not only GS mRNA and protein expression but also activity both in 
human osteoblastic cells and rat MSCs, but the non-canonical ligand Wnt5A was 
without any effect. Confirming our inhibitory observation, activation of Wnt signalling 
by overexpression of the degradation-resistant β-catenin was able to inhibit directly GC-
dependent transcriptional activity in the pMMTV (mouse mammary tumour virus) 
reporter assay in MG-63 cells. Furthermore, overexpression of stable β-catenin reduced 
the GC-induced GS mRNA level in MG-63 cells further supporting the specific 
involvement of β-catenin in the downregulation. Therefore, we can conclude that the 
Wnt/β-catenin pathway is able to inhibit GC target genes, GS in particular, in 
osteoblastic cells. 
 
 
5.2.3 Expression during osteoblastic differentiation  
 
GS activity was studied during the time course of the differentiation of rat MSCs, 
and found to be stimulated under the osteogenic conditions accordingly until the cells 
started to mineralize. At the onset of mineral deposition, GS expression and activity 
were markedly reduced. (Fig. 14.) GC induction of GS was also more potent in 
immortalized mature osteoblasts (HOB-03-CE6) than in preosteoblasts (HOB-03-C5) at 
the mRNA and protein expression levels as well as according to GS activity, but these 
cells were not assayed further to elucidate the full differentiation cascade. In addition, 
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the differentiation process cannot be analysed with MG-63 cells as these cells produce 
too little mineral even in the presence of osteogenic culture conditions. In many studies, 
glutamate signalling has been blocked with the NMDAR inhibitor MK801, a non-
competitive antagonist binding inside the ion channel and preventing calcium flow. Use 
of non-competitive inhibitors is favourable since glutamate in the culture medium 
prohibits the use of competitive ones. Furthermore, since glutamate is required for 
normal cell function and cells cannot be cultivated without it, agonist studies are not 
possible. In the rat MSCs, MK801 exposure delayed osteoblastic differentiation, and 
this treatment led to increased GS activity. The opposite effect was observed with the 
Wnt signalling pathway, but calcitriol delayed both the mineral deposition and GS 
activity indicating involvement of a separate mechanism in this respect. Nevertheless, 
GluR activity is required for osteoblastic differentiation, and GS seems to be regulated 
during the process.  
 
 
5.2.4 Effects on glutamate signalling 
 
The circulation of glutamate in and around cells is naturally an important regulation 
point of glutamate signalling. During the past ten years, glutamate signalling has been 
recognized as one potential control mechanism in bone cells, although its physiological 
role is still not totally clear. One enzyme regulating the intracellular glutamate 
concentration is GS, and based on our studies, it is expressed and regulated in 
osteoblastic cells. In studies with rat MSCs, the intracellular glutamate concentration 
was found to increase during osteogenic differentiation. Furthermore, all our observed 
changes in GS activity were, indeed, reflected directly in the intracellular glutamate 
level in osteoblastic cells: GCs decreased the amount of glutamate while inhibitors of 
GS (calcitriol, methionine sulphoximine and active Wnt signalling pathway) increased 
the concentration. Therefore, any factor affecting GS activity could alter the amount of 
the intracellular signalling molecule. (Fig. 14.) 
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Fig. 14. Schematic representation of GS expression and the corresponding intracellular 
glutamate concentration during osteoblastic differentiation as observed in our study. Temporal 
expression levels of, e.g., collagen type I, Cbfa1, ALP, and OCN are generally used to 
characterize the osteoblastic phenotype (Aubin et al., 1995). Due to its temporal expression 
pattern as well, GS could be even considered as a novel differentiation marker for bone 
formation.  
 
 
5.3 A novel mechanism for glucocorticoid inhibition of the Wnt 
pathway (III) 
 
5.3.1 Downregulation of Wnt signalling by glucocorticoids  
 
As Wnt signalling was observed to regulate GC target gene expression in 
osteoblastic cells, we next investigated whether GCs, for one, control Wnt signalling in 
these cells. GCs have been reported to weaken Wnt signalling in murine osteoblasts via 
a variety of routes or signalling molecules: GCs increase the degradation of β-catenin 
(Smith and Frenkel, 2005), upregulate Notch1 expression, known to inhibit Wnt 
signalling (Pereira et al., 2002; Deregowski et al., 2006), and increase sFRP1 
production (Wang et al., 2005). In human osteoblasts, GCs suppress the canonical Wnt 
signal, at least in part by increasing Dkk-1 expression (Ohnaka et al., 2004 and 2005). 
In our cell systems as well, GCs inhibited Wnt signalling in the TOPflash reporter 
assays. Supporting this, GCs were shown to inhibit expression of a known Wnt target 
gene, cyclin D1, an effect also seen previously by others (Takayama et al., 2006). 
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However, GCs only modestly, if at all, affected the degradation of β-catenin in our 
experiments. In fact, all the inhibitory effects of GCs were also seen in Wnt activity 
induced by the degradation-resistant β-catenin mutant. Therefore, a search for additional 
regulatory mechanisms was necessary. 
 
 
5.3.2 Localization of β-catenin 
 
β-catenin is found in three locations in the cells: at the membranes, in the 
cytoplasm, and in the nucleus. In addition to its stability, shuttling between these 
different compartments is an important regulator of β-catenin´s function regarding 
control of target gene expression. Liganded androgen receptor has been shown to induce 
the nuclear translocation of β-catenin (Mulholland et al., 2002; Pawlowski et al., 2002). 
Therefore, we were interested to examine whether GCs could affect the cellular 
distribution of β-catenin in osteoblastic cells. Our results indicated that GCs were able 
to translocate β-catenin to the cell membranes (Fig. 15.) thus inhibiting activity of Wnt 
signalling pathway. Although immunofluorescent staining showed clear effects with 
both LiCl, a GSK3β blocker, and GCs supporting the reporter results, methodological 
problem in this assay makes it difficult to specifically observe the amount of 
fluorescence at membranes and thus to obtain accurate quantitative data. Nevertheless, 
at a very short timepoint, 15 min, there was no difference seen in the LiCl-induced 
nuclear import of β-catenin with or without GCs giving support for the regulation of 
nuclear export, in particular. In agreement with our results, Guan and co-workers have 
also shown GCs' ability to, through yet unknown mechanism, relocate β-catenin to the 
cell membranes in rat mammary epithelial tumour cells (Guan et al., 2004).  
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Fig. 15. GCs (Dex) inhibited the nuclear translocation of β-catenin by increasing its 
relocalization to cell membranes in MG-63 cells (3 h). A GSK3β blocker, LiCl, was used to 
activate the Wnt signalling pathway. Images were taken with a confocal microscope (scale bar 
50 µm). (From original publication III) 
 
 
5.3.3 Role of calreticulin  
 
At the cellular level, the biological effects of GCs are mediated by binding of the 
steroids to their modular receptor proteins, GRs. By using several GR deletion 
constructs, we demonstrated that the region of GR required for the Wnt inhibition was 
located in the DBD of the receptor molecule. In addition to its role for the 
transcriptional activity of the receptor, DBD contains a NES especially via the transport 
molecule CRT, which has been found to be involved in the regulation of nuclear 
hormone receptors like GR. Specifically, CRT binds to the highly conserved 
KXGFFKR motif present in the cytoplasmic domains of integrin subunits. The highly 
homologous sequence, KxFFKR, is present in all known members of the steroid 
receptor family. This amino acid sequence is found between the two zinc finger motifs, 
which are involved in the binding of the receptor molecule to the target DNA (Fig. 16.). 
Thus, CRT powerfully inhibits the transcriptional activity of the steroid receptors by 
altering the functional properties of this region (Burns et al., 1994; Dedhar et al., 1994). 
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Fig. 16. The DBD of human GR is shown in its classical zinc finger representation. The 
conserved residues KVFFKR (underlined, amino acids 442-447) are known to be involved in 
the interaction with CRT. (From original publication III) 
 
 
Overexpression of CRT either by genetical manipulation or by treatment with 
thapsigargin inhibited Wnt activity and enhanced the inhibitory effect of GCs in both 
reporter assays and immunofluorescent staining in osteoblastic cells. Providing further 
support, the inhibitory effect of GCs on Wnt signalling was compromised when CRT 
expression was silenced with RNA interference technique and CRT siRNA. More 
importantly, these effects were also seen in the expression of endogenous Wnt target 
gene, cyclin D1. By investigating the mechanism in more detail, three of the six amino 
acids of the KVFFKR region, namely F444, F445, and R447, were found important. 
Deletion of each of these three amino acids has been reported to weaken interaction of 
CRT with GR and to inhibit the nuclear export of GR, the two Phe-residues being the 
most important ones (Black et al., 2001). Since the amino acid changes impairing the 
transcriptional activity of GR were not the same as those decreasing Wnt activity, we 
were further convinced that the inhibition of Wnt pathway is not directly linked to the 
transcriptional events caused by GR, instead being attributable to the GR-mediated 
nuclear export of β-catenin.  
In our co-immunoprecipitation experiments, human GR and β-catenin were found 
in the same immunocomplex. Supporting this hypothesis, others have shown that the 
interaction site of GR with β-catenin was located to the DBD of the receptor (Takayama 
et al., 2006), and for β-catenin, the first five repeats of the armadillo domain were 
sufficient for GR binding. The double mutant of GR was still able to interact with        
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β-catenin in our co-immunoprecipitation experiments. However, CRT and β-catenin 
were found in the same immunocomplex only in the presence of GR, an interaction 
clearly impaired by the elimination of the two Phe residues from GR. Therefore, this 
further proves that β-catenin could be co-transported with GR from the nucleus. (Fig. 
17.) 
In the absence of GR, CRT was also able to significantly inhibit Wnt signalling 
although we did not observe any clear effects in the localization of β-catenin in our 
immunostaining experiments, but then again, this method is not quantitative. Although 
β-catenin localization and function can be regulated by the degree of tyrosine 
phosphorylation (Piedra et al., 2001), in particular at Tyr-654, and CRT has been shown 
to decrease tyrosine phosphorylation of β-catenin (Fadel et al., 2001), basal Wnt activity 
or its modulation with CRT were not affected by the potential Y654A substitution of   
β-catenin in human osteoblastic cells. Therefore, the mechanism, by which CRT alone 
inhibits Wnt activity in these cells involves possibly more extensive phosphorylation 
events or other mechanisms.  
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Fig. 17. Hypothesized model for the involvement of GR in the GC-induced subcellular 
relocalization of β-catenin and thereby in the regulation of Wnt target genes in osteoblastic cells 
as observed in our study. CRT was also shown to inhibit Wnt signalling alone in the absence of 
GCs, but the mechanism is still unknown. Selected Wnt target genes, related to bone and 
cartilage, are also listed in the figure (from Wnt Homepage, 2008, and original publication II).  
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5.4 Effects of ultrasound exposure on osteoblastic cell signalling (IV)  
 
5.4.1 Ultrasound-induced Wnt signalling pathway 
 
Therapeutic US has been shown to be beneficial in the treatment of bone fractures 
(Claes and Willie, 2007; Khan and Laurencin, 2008). However, the molecular 
mechanisms behind this phenomenon are still unclear. Since US can be considered as 
mechanical energy in the form of high-frequency acoustical pressure waves, it could be 
hypothesized that it primarily affects cell membranes and signalling cascades 
originating from there. Therefore, we investigated the potential effects of US on the 
activity of Wnt signalling pathway in human osteoblastic cells.  
In our experiments, lower level US intensities (41 - 326 mW/cm2), indeed, showed 
a positive effect on Wnt activity as measured by the TOPflash reporter assay in MG-63 
cells, though the results remained just below the level of statistical significance. With 
one higher US intensity (407 mW/cm2), however, the TOPflash reporter activity, and 
thus Wnt signalling pathway, was significantly stimulated, and US exposure also 
potentiated the LiCl-induced Wnt activity. Therefore, this intensity setting was used for 
the further studies, while the temporal parameters were constant throughout the 
experiments, i.e., frequency of 1.035 MHz, pulse repetition frequency of 1 kHz, 200 µs 
burst length, and duty cycle of 20%. Giving further confirmation for the reporter results 
obtained, US exposure inactivated GSK3β, leading to increased nuclear translocation of 
β-catenin in MG-63 cells shortly after the US exposure. This is apparently the first study 
where a reporter assay has been utilized in bone cells to evaluate the biological effects 
of US exposure.  
 
 
5.4.2 Thermal effects on Wnt signalling 
 
Many US set-ups in vitro are susceptible to considerable temperature elevation due 
to fact that they often include sound absorbing components, for example, plastic cell 
culture plates which absorb part of the US wave and convert it to heat. Bony in vivo 
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targets are also likely to suffer temperature accumulation especially on soft tissue-bone 
interface. Thereby, some of the effects of therapeutic exposures could also be caused by 
this thermal component. Despite this tendency to temperature rise, in many studies the 
temperature increases have only been estimated or sometimes just completely ignored. 
Thereby, in this study the temperature profiles and values were measured directly from 
the wells. With the US parameters showing the highest Wnt activation (407 mW/cm2), 
the temperature was increased to 47.6°C. This rather high temperature elevation 
indicates that Wnt activity might be temperature-dependent under these circumstances. 
With plain heat, Wnt activity increased at 44.8°C and peaked at 46.6°C, but at higher 
temperatures the activity became radically reduced. Nuclear localization of β-catenin 
was also evident with the plain heat corresponding to the reporter results. Therefore, the 
thermal component of the US setting used seemed to be important. Despite the elevated 
temperatures, during either thermal or US exposures, the viability of the cells was not 
compromised as apoptotic or necrotic markers were not markedly upregulated at 
timepoints where there was Wnt activation. In fact, Wnt signalling has been reported to 
attenuate osteoblast apoptosis (Bodine, 2008). Furthermore, the cells were exposed to 
the highest temperatures for only a fraction of the single 10 min exposure. When the 
thermal dose values for US and heat treatments were calculated and compared, it was 
observed that as an average, the dose value for the highest US exposure was very close 
to the dose value for 47.5°C heat treatment. This temperature is approximately 1°C 
higher than the most efficient heat exposure temperature implying that even more 
effective Wnt activation through US’s heat component could be created using intensity 
approximately 366 mW/cm2. 
 
 
5.4.3 Non-thermal component of ultrasound in Wnt activation 
 
Although Wnt activity did not reach statistical significance with lower US 
intensities, a reproducible stimulatory trend was observed. As the US induced 
temperatures and corresponding heat doses were low or very low with these intensities, 
it is possible that US could contain also a non-thermal component that activates Wnt 
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signalling. In an attempt to lower the thermal dose during the US exposures with the 
highest intensity, we performed similar experiments using a cooler US setup: the cells 
were cultured normally at 37°C incubator, but the water bath used for the US exposures 
was adjusted to 30°C instead of 37°C. The thermal dose with this cooler setup was not 
elevated with the US intensity used, but US reproducibly stimulated Wnt activity 
slightly but significantly providing evidence for the presence of the non-thermal US 
component as well. The viability and morphology of the cells were found to be normal 
with this setup.  
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6. DISCUSSION 
 
Various signalling pathways have been reported to be important for osteoblast 
differentiation and bone formation (Deng et al., 2008; Heino and Hentunen, 2008). In 
addition, cross-talk between some of these different cascades can be assumed to occur 
in the bone environment. Cells are complex units, in which multiple pathways function 
simultaneously and affect each other’s actions to variable degrees depending on the 
relative strengths of the active pathways in question. Therefore, the factors and 
mechanisms controlling the activity of these various cascades are in a strategic position 
with respect to bone cell function and bone health.  
 
 
6.1 A common target gene for glucocorticoid and Wnt signalling 
pathways in osteoblastic cells 
 
GS is a multimeric enzyme composed of 8 subunits of 42 kDa in size in mammals. 
Expression of GS in the mammalian systems is regulated both at the transcriptional as 
well as the translational level, and is controlled in response to end-product (Sarantos et 
al., 1994a; Lie-Venema et al., 1998; Labow et al., 1999; Eisenberg et al., 2000). Its 
function has been characterized already in the 60´s, especially in prokaryotes and plants, 
and later in mammals as well. Brain tissue has been the principal research target, but GS 
expression is clearly not restricted to the nervous system. GS has a vital role in 
controlling the intra- and extracellular levels of both glutamate and glutamine. Lately, 
mutations in this enzyme have been reported to lead to severely reduced enzymatic 
activity, which is fatal for newborns (Häberle et al., 2006). GS is solely responsible for 
the de novo synthesis of glutamine. Since both glutamate and ammonia are relatively 
abundant in the cytoplasm and therefore not limiting, the rate of glutamine formation is 
highly dependent upon the activity of GS. Although there are other mechanisms to 
remove glutamate from the cells, such as controlled exocytosis and conversion to other 
molecules, GS also naturally plays an important role in this respect. While it may be 
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wrong to underestimate glutamine´s potential ability to control osteoblast function, it is, 
however, more likely that glutamate is the more central player as a characterized signal 
transducer. Nevertheless, regulation of GS has a vital role, and our proteomic study 
revealed an open field in bone biology as we characterized GS to be a novel target for 
GC signalling in bone.  
Three genes involved in glutamate metabolism, encoding GS, ornithine 
aminotransferase, and GLT-1 have been identified as Wnt/β-catenin target genes in 
mouse liver (Cadoret et al., 2002). Overexpression of these genes was observed in 
response to Wnt activation. GS expression is known to be induced via an upstream 
enhancer located -2.5 kb, and this property is dependent on the function of β-catenin in 
mice (Kruithof-de Julio et al., 2005). In silico analysis revealed also potential TCF/Lef1 
binding sites in the promoter region of mouse GS (Loeppen et al., 2002). Once again, 
there is not, however, knowledge about the regulatory regions of the human gene, yet. 
Somewhat surprisingly, the effect of Wnt signalling in osteoblastic cells was the 
opposite to the results observed in mouse liver (Cadoret et al., 2002). This differential 
GS control might simply be due to tissue or species specific regulation, or attributable to 
the presence of particular co-regulators. Supporting this, the liver GS responds very 
differently to feedback inhibition compared to the brain form of this enzyme, and GS 
molecules isolated from different tissues of even same species are identical in sequence 
yet exhibit different biochemical properties, i.e., there must be some post-translational 
modifications or other regulatory mechanisms involved (Eisenberg et al., 2000). 
Furthermore, GS expression in the liver is highly restricted to specific cells surrounding 
the terminal hepatic venules (Gaunitz et al., 2005). Additional confirmation comes from 
a recent study, where Krox20, a factor expressed by osteoblasts and chondrocytes, was 
oppositely regulated by GCs and Wnt signalling (Leclerc et al., 2008). Therefore, a 
functional cross-talk between GC and Wnt signalling seems to exist in osteoblastic 
cells. These signalling pathways share a temporal activation pattern for proper 
osteoblastogenesis, and since both cascades are crucial, the communication is therefore 
reasonably justified. Since it is a common target gene for both GC and Wnt signalling 
pathways, GS provides us with a new tool to study the effects of these cascades in the 
bone environment. Specific antibodies, blockers, and assays are available for this 
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enzyme. However, in vivo studies are more demanding as this enzyme is vital, and 
knocking it out would presumably be detrimental.   
 
 
6.2 Regulation of glutamate signalling through the control of glutamine 
synthetase in osteoblastic cells 
 
The involvement of GS in the osteoblastic differentiation and its regulation during 
that process is a novel aspect in the field of bone biology. According to our results, GS 
expression and activity were altered during the differentiation process at least in the rat 
MSCs studied here. When the cells matured, GS activity was increased but declined 
rapidly to a lower level at the stage of mineralization. Delayed differentiation of 
osteoblasts by inhibition of glutamate signalling by treatment with an NMDAR 
antagonist confirmed our results. Therefore, GS could be even considered as a new 
marker for osteoblast differentiation. With respect to other markers, inhibition of 
glutamate signalling has been reported to prevent also increases of ALP and OCN 
(Hinoi et al., 2003). Furthermore, GS has been previously linked to differentiation of 
other cells such as intestinal epithelial cells and adipocytes (Weiss et al., 1999; Miller 
and Carrino, 1981).  
Even more importantly, all the observed changes, either inductive or inhibitory, in 
GS activity were reflected in the intracellular glutamate concentration of osteoblastic 
cells. In addition to GS, GCs have been reported to induce mGluR5 and EAAT-1 
expression in MG-63 cells (Kalariti et al., 2007), i.e., these steroids could control all 
aspects of glutamate cycling and turnover. Interestingly, when comparing GS activity 
results to the corresponding intracellular glutamate concentration, it seems evident that 
glutamate is very efficiently circulated in the cells, and in the presence of GCs, this 
turnover needs to be greatly enhanced to maintain a relatively high enzymatic activity. 
Osteoblastic cells are known to gain a more glutamatergic phenotype as they 
differentiate (Genever and Skerry, 2001), and this was also observed in our studies. 
There is no direct evidence of possible Wnt control of glutamate signalling, but GLT-1 
83 
 
 
was reported to respond to Wnt signalling in mouse liver (Cadoret et al., 2002), and in 
glioma cells, Wnt1 regulates the expression of the glutamate transporters (Jimenez et 
al., 2003). Wnt1 has, however, a limited expression profile in adult mammalian 
organisms.  
Furthermore, the role of glutamate might be even more extensive in the bone 
environment as it can be further converted to other neuronal signalling molecules. For 
example, glutamate decarboxylase catalyzes the formation of γ-aminobutyric acid 
(GABA) from glutamate. GABA is another important neurotransmitter, and 
interestingly, functional GABAB receptors have been reported to be expressed in 
osteoblasts (Fujimori et al., 2002). Another enzyme, glutamate carboxylase, mediates 
the conversion of glutamate to γ-carboxyglutamate (Gla), which incorporates Ca2+ ions 
into hydroxyapatite. OCN is actually one of the major Gla-containing proteins within 
the bone tissue (Bügel, 2003). Furthermore, many other neurotransmitters such as 
vasoactive intestinal peptide, substance P, neuropeptide Y, calcitonin gene-related 
peptide, serotonin, and dopamine have recently been identified in bone (Mason, 2004; 
Elefteriou, 2008). It is, however, still unclear whether these other transmitters contribute 
to control of bone cell phenotype, but a clear neuro-skeletal link in bone does exist. 
Osseus cells naturally communicate in the bone environment. Systemic signals 
received by osteoblasts, residing on the bone surface, are transmitted to osteocytes 
within the bone structure, while stress-generated signals perceived by osteocytes are 
transmitted to osteoblasts (Civitelli, 2008). In addition, an exchange of information with 
osteoclasts is equally important (Matsuo and Irie, 2008). Since all bone cells are 
presumably able to participate in glutamate metabolism, it could be hypothesized that 
regulation of glutamate signalling could influence the balanced activities of these cell 
types. Thus, glutamate may represent a crucial mediator in the intercellular 
communication network. In addition, changes in bone environment happen relatively 
slowly, taking weeks or months. On the other hand, signalling cascades involved in 
regulation of bone cell function, glutamate signalling in particular, can respond very 
rapidly. This raises a question, why would bone cells need to control signalling events 
within seconds and minutes in such a sophisticated way. It is widely known, that bone 
remodelling responds to mechanical loading. Short durations of loading are sufficient 
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for evoking a maximal, long-lasting osteogenic response, and cells become 
progressively more responsive to loading. The rapid events are able to launch a chain of 
reactions which might then take longer to proceed. This mechanism has been postulated 
to be linked to the function of glutamate, i.e., it is involved in bone cell memory 
(Spencer and Genever, 2003). Therefore, glutamate signalling could be considered as an 
especially good target for maintaining bone health. 
 
 
6.3 A novel mechanism for glucocorticoid receptor-mediated Wnt 
inhibition in osteoblastic cells 
 
One powerful way to control gene expression by signalling pathways is to regulate 
the subcellular compartmentalization of specific transcription factors. The nuclear-
cytoplasmic trafficking of GR is an important process in regulating the expression of 
GC target genes, and the same applies for β-catenin and Wnt target genes. Molecules 
smaller than ~40 kDa may in principle freely diffuse through the nuclear pore but larger 
ones require facilitated import mechanisms. Specific signal sequences on the substrate 
are usually required, and these sequences are recognized by soluble receptors called 
karyopherins or importins. The NLS binds to importin-α, which then binds to importin-
β. The complex docks into the nuclear pore by binding to nucleoporins and the complex 
is internalized with the aid of GTPase/Ran. (Pemberton and Paschal, 2005) GR utilizes 
this classical import mechanism (Freedman and Yamamoto, 2004), but β-catenin 
appears to enter the nucleus independent of importin-α/β (Fagotto et al., 1998). Instead, 
it seems to interact directly with the nuclear pore and can enter the nucleus without 
soluble transport factors. In fact, β-catenin and importins are structurally related: both 
molecules contain the so-called armadillo repeats which are necessary for the nuclear 
translocation (Funayama et al., 1995). β-catenin could even behave as an import 
receptor for other molecules, like Lef-1 (Asally and Yoneda, 2005). Therefore, GR and 
β-catenin do not compete for the same import mechanisms.  
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Nuclear export processes are, in general, divided into chromosome region 
maintenance 1 (CRM1/exportin 1) -dependent and -independent types (Fornerod et al., 
1997). Other exportins also exist, but are more cargo specific and include CAS (cellular 
apoptosis susceptibility protein), Msn5, importin-13 and exportin-t. Leptomycin B is a 
specific inhibitor of nuclear export of leucine-rich NES bearing proteins, and this 
antibiotic is widely used to study the CRM1-dependent export mechanisms. GR does 
not contain a classical leucine-rich NES and its export has been found to be insensitive 
to leptomycin B treatment suggesting that it is not a transport substrate for CRM1 (Liu 
and DeFranco, 2000). As a matter of fact, the DBDs of diverse nuclear receptors, 
including GR´s, function as NESs (Black et al., 2001). This region contains an 
interaction site for a chaperone molecule CRT, which is a multifunctional Ca2+-binding 
protein of the endoplasmic reticulum (Gelebart et al., 2005). It regulates intracellular 
calcium homeostasis at several points, e.g., the calcium storage capacity of endoplasmic 
reticulum, calcium signalling, and it serves as a chaperone in the folding of newly 
synthesized proteins as well as in modulation of cell adhesion. CRT can be divided into 
three distinct structural and functional domains N, P, and C: the N domain interacts with 
nuclear receptors while P and C contain high-affinity Ca2+-binding sites. The KDEL 
sequence in the C-terminus of CRT is responsible for the retention of these proteins in 
the endoplasmic reticulum. (Nakamura et al., 2001), but CRT can also be found in the 
nucleus since it contains a NLS (Opas et al., 1991). This nuclear localization can even 
be enhanced by the interaction with GR (Roderick et al., 1997). Indeed, Holaska and co-
workers (Holaska et al., 2001) have characterized CRT as a receptor for the nuclear 
export of GR. 
 Cellular β-catenin can also exit the nucleus independent of CRM1 (Wiechens and 
Fagotto, 2001), but its detailed export mechanism is still under study. A few potential 
mechanisms have been proposed, though: β-catenin could be co-exported along with 
APC (Henderson, 2000), or Ran binding protein 3 may antagonize the nuclear 
accumulation of β-catenin despite its role as a CRM1-associated nuclear export factor 
(Hendriksen et al., 2005). In addition, nuclear-cytoplasmic shuttling of Axin could 
regulate the intracellular distribution of β-catenin (Cong and Varmus, 2004). Cells may 
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use multiple export mechanisms for β-catenin in order to inhibit Wnt signalling in 
different ways depending on the cell´s requirements (Thorne and Gottardi, 2005).  
In addition to its well-known chaperone function, CRT is involved in the control of 
many cellular events such as molecular trafficking as well as modulating the activity of 
various signalling pathways (Fig. 18). According to our results, the interaction of GR 
with both CRT and β-catenin was crucially involved in the GC-mediated β-catenin 
translocation to the cell membranes and the subsequent Wnt inhibition. Thus, β-catenin 
could be co-transported from the nucleus with GR presenting thus an additional 
mechanism for the nuclear export of β-catenin and possibly for GIO. This mechanistic 
model could also apply more widely to other nuclear receptors as well, since they share 
common DBDs, and receptors, such as vitamin D receptor, estrogen receptor, androgen 
receptor, and progesterone receptor were also inhibitory in the TOPflash reporter assays 
(our unpublished observations), as expected (Shah et al., 2003; Mulholland et al., 
2005). Therefore, competition between GR and other receptors capable of binding CRT 
has been reported to influence GR function (Black et al., 2001). However, the effects 
could also involve other mechanisms, like phosphorylation events, and it is not studied 
whether all these receptors are able to translocate β-catenin. Furthermore, GCs could 
still modulate also other aspects of Wnt signalling, like the interaction of β-catenin and 
TCF/Lef. In addition, a member of the LIM protein superfamily, FHL2, has been shown 
to interact with β-catenin and to potentiate β-catenin nuclear translocation and thus Wnt 
signalling, and, above all, expression of ALP and Cbfa1 in osteoblastic cells. 
Interestingly, GCs were found to upregulate the expression of FHL2. (Hamidouche et 
al., 2008)  
Bone formation may proceed in two ways. In intramembranous ossification, the 
osteoblasts deposit matrix on a membranous network within the bone. Alternatively, in 
endochondral bone formation, a cartilage model is created by the chondrocytes which is 
later replaced by the osteogenic cells and bone tissue. Most of the bones are formed by 
this latter mechanism. (Olsen et al., 2000) Interestingly, the chemical cocktails used to 
direct mesenchymal cell commitment in vitro can vary and are even somewhat 
overlapping since GCs can be used to direct MSCs towards both osteoblastic and 
chondrogenic differentiation (Derfoul et al., 2006). At the progenitor stage, these 
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lineages differentiate into either osteoblasts or chondroblasts, for example, via 
regulation of the level of β-catenin and lineage-specific transcription factors. 
Furthermore, the unspecified factors in the serum used in cell cultures represent 
variability. Could the GC-induced β-catenin translocation and inhibition of Wnt 
signalling be sufficient to redirect osteoblasts to chondrocytes, is an intriguing aspect 
concerning bone health. In GIO, could the bone loss be due to GC-induced excess 
cartilage formation, although this could again be used as a model for bone formation. 
Nevertheless, knowledge how these signalling pathways are regulated and affect bone 
formation and functional balance between osteoblasts and osteoclasts could help in 
preventing or treating GIO.  
 
 
 
 
Fig. 18. Involvement of CRT in different signalling pathways in the cellular environment. CRT 
= calreticulin; CaM = calmodulin; CaMKII = calmodulin-dependent kinase II; PI3K = 
phosphatidylinositol 3-kinase; ERK = extracellular signal-regulated protein kinase; NF-AT = 
nuclear factor of activated T-cells; GSK3 = glycogen synthase kinase 3. (Reprinted from Szabo 
et al., 2006, with kind permission of Landes Bioscience.) 
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Calcium binding to CRT is necessary for its direct interaction with the DBD and for 
the nuclear export of GR (Holaska et al., 2002). Therefore, all factors affecting the 
ability of CRT to bind calcium are apparently able to regulate the nuclear export 
function of GR. Stress response-induced release of intracellular calcium has been 
reported to upregulate CRT expression (Llewellyn et al., 1996), which was also 
observed in our osteoblast-like cells. In addition, CRT-induced calcium release from the 
endoplasmic reticulum could thus regulate signalling pathways indirectly from this site. 
Via calcium signalling, CRT could also alter the nuclear-cytoplasmic shuttling or 
calpain-mediated degradation of β-catenin (Li and Iyengar, 2002; Benetti et al., 2005). 
Release of calcium from the endoplasmic reticulum, for example, is known to activate 
calcineurin, which is one way to induce nuclear translocation of a transcription factor 
NF-AT (nuclear factor of activated T-cells). The calcineurin pathway could also 
regulate β-catenin nuclear trafficking. (Szabo et al., 2006) The intracellular calcium 
level controls many cellular processes, and changes in calcium levels are very rapid. 
Therefore, even small changes in the intracellular calcium levels can produce significant 
outcome. Modulation of extracellular calcium with EGTA (ethylene glycol tetraacetic 
acid) inhibited powerfully Wnt signalling in the TOPflash reporter experiments (our 
unpublished data) indicating that factors affecting calcium levels may contribute to Wnt 
signalling as such. Supporting this, constitutive expression of CRT in osteoblasts 
inhibited OCN expression and mineralization (St-Arnaud et al., 1995 and 1996), which 
could easily be explained by the negative effects on Wnt signalling observed in our 
experiments. Rapidly proliferating cells tend to have an increased expression of CRT 
(Wheeler et al., 1995), and in concordance, endogenous CRT expression was found to 
decline during osteoblastic differentiation. This downregulation does not, however, 
simply explain the decreased GS activity observed in our cell model at the onset of 
mineralization. In view of the essential role of calcium for bone homeostasis, it is not 
far-fetched to postulate that calcium levels could be modulated and at least a few 
osteoblast specific functions could be mediated via changes in calcium signalling. 
Interestingly, a calcium binding protein S100A4, characterized as a negative regulator 
of osteoblast differentiation (Duarte et al., 2003), has recently been identified as a Wnt 
target gene in bone, too (Hopwood et al., 2007).  
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6.4 Effects of ultrasound on osteoblastic cells via induction of Wnt 
signalling  
 
In most cases, bone fractures heal without any problems simply by new bone 
formation. However, in 5-10 % of all fractures, the healing process does not proceed 
normally. In delayed unions, the fracture healing takes longer than usual, while in non-
unions the broken bone fails to heal due to lack of stability or limited blood supply. 
Non-invasive, low-intensity US technology has been reported to accelerate the natural 
healing process of fresh fractures and to resolve non-unions (Claes and Willie, 2007), 
and it is becoming a commonly used therapy. It has been shown to increase osteoid 
thickness, mineralization and bone volume in patients with delayed unions (Rutten et 
al., 2008). The external bone stimulator, EXOGENTM bone healing system from 
Smith&Nephew Inc. has been shown to improve the fracture healing at each stage of the 
process: inflammation, soft callus formation, mineralization of the callus, and 
remodelling. Although the importance of US for bone health is indisputable, the cellular 
mechanisms that account for this property are not fully understood. US has been 
reported to stimulate nitric oxide production in human osteoblasts (Reher et al., 2002), 
which can lead to VEGF-A (vascular endothelial growth factor A) expression and 
enhanced vascularization (Wang et al., 2004). US also stimulates osteogenic marker 
expression and mineral deposition (Naruse et al., 2003; Unsworth et al., 2007), 
regulates TGF-β expression (Harle et al., 2005), and alters the OPG/RANKL ratio and 
inhibits osteoclast differentiation (Maddi et al., 2006; Yang et al., 2005). However, the 
US equipments, parameters, and experimental settings in all studies are not necessarily 
fully comparable which might explain some of the diversity of current results. 
During the past few years, mechanical loading and fluid shear stress have been 
reported to activate the canonical Wnt signalling pathway in mouse and rat primary 
cells as well as clonal osteoblastic cells (Lau et al., 2006; Hens et al., 2005; Robinson et 
al., 2006; Armstrong et al., 2007; Case et al., 2008). In addition, mechanical stimulation 
of bone has been shown to reduce osteocytic expression of Sclerostin (Robling et al., 
2008). The cellular effects of US are most likely caused by the mechanical energy of the 
US waves being transferred to tissues exposed. Therefore, US shares some of the 
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features of mechanical loading on bone (Perry et al., 2009). There are, however, no 
previous reports on the effects of therapeutic US on the Wnt signalling in general or in 
bone, in particular. In our US experiments, Wnt signalling pathway was, indeed, 
activated in osteoblastic cells, though statistically significantly with only higher 
intensities. In addition, activation showed rather high temperature dependence since 
Wnt pathway was activated also by the heat treatment, and the US setting used evoked a 
rather marked temperature elevation as well. In fact, there are no previous studies on 
hyperthermia and Wnt activity either, and also thermal effects have been shown to be 
positive for bone formation (Leon et al., 1993; Ye et al., 2006). Nonetheless, US 
displayed also a small but significant distinct, non-thermal activating component, 
perhaps evidence of a potential dual action. Therefore, optimization of the exposure 
conditions would be required to enhance the ultrasonic factor to achieve more 
unequivocal results. In support of our observations, precise regulation of β-catenin is 
one of the many factors required for fracture healing as many Wnt ligands and receptors 
were found to be selectively upregulated during bone healing (Chen et al., 2007b; 
Silkstone et al., 2008). Furthermore, in patients with non-unions, osteoblasts showed 
altered viability, osteogenic differentiation, and downregulation of multiple vital 
signalling pathways, including the Wnt pathway (Hofman et al., 2008). In another 
study, the amount of osteoprogenitors was decreased in the bone marrow of patients 
with non-unions (Hernigou et al., 2005). Therefore, increased Wnt activity by US might 
improve that situation by stimulating osteogenic commitment. Close to our study, 
Takeuchi and co-workers also observed a small but significant increase in nuclear        
β-catenin level in US exposured articular cartilage (Takeuchi et al., 2008). However, 
they did not study Wnt activity but evaluated the effects of US on the 
phosphatidylinositol 3- kinase/Akt pathway.   
As originating from the cell membrane, activation of Wnt pathway by US is likely. 
It is, however, still unclear, what are the exact molecular events that activate the 
pathway following US exposure. Are the Wnt receptors activated non-specifically, 
which would implicate a more universal activation of signalling pathways not 
necessarily very reasonable, or does US stimulate specific secretion or release of 
distinct ligands, are questions of great importance. Direct release of β-catenin from the 
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cell-cell contacts is not, however, a likely inductive mechanism to explain the effects of 
US as we also observed the inactivation of GSK3β, an upstream event of β-catenin 
stabilization. Wnt signalling has been shown to enhance the sensitivity of osteocytes to 
strain (Robinson et al., 2006; Bonewald and Johnson, 2008), and Wnt activity could be 
a link between mechanical loading and bone adaptation. Since also the glutamate 
receptor subunit expression is reported to be modulated with mechanical loading 
(Szczesniak et al., 2005), and loading causes glutamate accumulation in rat osteoblasts 
(Ho et al., 2005), US exposure could also have an impact on glutamate signalling either 
directly or indirectly via Wnt signalling and/or GS activity. 
To summarize, US was shown to activate the Wnt signalling pathway in human 
osteoblastic cells. The pathway showed also thermal dependence, which could make US 
an even more practical therapeutic tool as US stimulation seems to have two different 
components which both have a stimulatory effect on Wnt signalling. In addition, the 
synergistic action with GSK3β inhibitors could have important clinical implications by 
permitting a reduction in the doses of some of the pharmacologic treatments given in 
combination with mechanical stimulus and/or heat. Nevertheless, US is a good tool to 
target loading and/or heat to deep tissues, and it possesses several advantages when 
compared, for example, to electromagnetic waves (Diederich et al., 1999). In addition to 
activating positive signalling pathways, US can of course facilitate fluid flow through 
acoustic streaming, thus increasing nutrient delivery and waste removal which may also 
contribute to the healing process. 
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6.5 Future perspectives 
 
The results presented in this thesis provide novel information about the 
differentiation of osteoblastic cells and the signalling events related to this process. In 
the future, it would be important to determine, whether the described complex cross-talk 
between GC, Wnt, and glutamate signalling pathways is present in stromal cells, 
whether it controls osteogenic commitment of MSCs, and to what extent osteoclasts and 
osteocytes are involved. Bone cell co-cultures, for example, could provide novel 
information how the intercellular communication is achieved. It would also be essential 
to study, what is the final outcome of these observations in vivo, and whether 
therapeutic US is able to modulate all these pathways and their interactions. 
Furthermore, characterization of the human GS promoter region would provide a 
practical approach to study the regulation of GS more efficiently. Further investigation 
of the role of CRT during osteoblast commitment and differentiation could also reveal 
novel aspects for the control of all these signalling pathways. In addition to the steady-
state results presented in this thesis, live cell imaging could give more detailed 
information about the molecular trafficking of β-catenin, GR and CRT. However, in 
order to answer these questions, further studies will be required.  
The future challenge is to solve how to convert all this information into safe and 
effective therapeutic applications to benefit patients with various bone diseases, like 
GIO. A better comprehension of the disorders of bone formation will require deeper 
insights into the complex regulatory events occurring during osteogenic differentiation. 
We are just beginning to understand the mechanisms controlling bone cell function and 
bone biology, and the corresponding pathology. Detailed information about these 
molecular mechanisms could help in the design and development of well-targeted 
therapies. Nonetheless, one should be aware of the difficulties in targeting these 
pathways. Wnt signalling is a complex cascade involving simultaneously many 
molecules and tissues (Chan et al., 2007). The role of glutamate as a neurotransmitter 
restricts its use for targeting only skeletal sites, though this might be overcome by 
designing compounds unable to pass through the blood-brain barrier. GR is already a 
well recognized drug target although its disadvantages are well known since it also 
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possesses such a wide variety of physiological actions. Interestingly, impaired Wnt/β-
catenin signalling has recently been associated with pathogenic factors involved in 
atherosclerosis, coronary artery disease, hyperlipidemia, hypertension, and diabetes in 
addition to various cancers. These even surprising results of Wnts´ multiple actions 
were observed in a large Iranian family with a single mutation in LRP6 (Mani et al., 
2007). Patients with metabolic syndrome and type I diabetes alone, are indeed 
associated with low bone mineral density and osteoporosis. Therefore, the data received 
from the bone cell studies could be applied also outside the field of bone biology. 
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7. SUMMARY AND CONCLUSIONS 
 
GCs are intriguing hormones as their effects on osteoblasts depend clearly on the 
differentiation status of the cells. They are required for the early osteoblastic lineage 
commitment and differentiation, but as the cells mature, GCs change to being negative 
regulators of osteoblast function and bone formation leading to osteoporosis especially 
when these steroids are used at pharmacological dosages. The molecular mechanisms 
behind this phenomenon are, however, still not fully understood.  
The experiments presented in this thesis were designed to elucidate the molecular 
mechanisms of GCs involved in controlling osteoblast differentiation and function. Our 
proteomic studies identified expression of a novel GC target gene in human osteoblastic 
cells. GS provides a new tool to study the effects of GCs on osteoblast differentiation 
and function. It was found to be an essential enzyme linking several signalling pathways 
important for bone, and its strict regulation could, for example, explain both the 
negative effects of GCs as well as the beneficial action of Wnt on bone (Fig. 19.). Wnt 
signalling could through downregulation of GC signalling and GS activity, modulate the 
amount of glutamate and the signal transduction evoked by this transmitter. Since it is 
now possible to activate Wnt signalling by exposing osteoblasts to US, it might also be 
used to influence the glutamate signalling in the fracture areas and thus promote healing 
processes via several pathways. This study also provided a novel mechanism to explain 
how GCs can downregulate Wnt signalling directly, which could be considered as an 
additional mechanism for the development of GIO.  
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Fig. 19. Schematic presentation of the regulation of the interplay between GC, Wnt, and 
glutamate signalling pathways in bone, based on the results obtained in this thesis work. Also a 
potential molecular mechanism explaining the beneficial effects of therapeutic US on fracture 
healing is presented. The role of other bone cells and factors affecting glutamate signalling 
directly remains to be elucidated. 
 
 
Full comprehension of the disorders of bone formation will require insights into the 
complex regulatory events occurring during osteogenic differentiation, and the neuro-
skeletal integration is becoming even more evident. Understanding cross-talk between 
different signalling pathways important for bone could provide necessary background 
for clinical studies and pharmacological design. More profound knowledge about the 
molecular mechanisms involved in bone cell differentiation and function could benefit, 
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among many things, treatment or prevention of GIO, fracture healing processes, tissue 
engineering technology with stem cells as well as assisting in the development of bone- 
friendly GC pharmaceuticals. 
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